Diabetics with GE insulin intolerance need help!



> T1 since 1962(42years) 2x HypurinBovine/Lente mixed with
> LillyIletinIIPork/Regular last A1C 5.7 on a normal 4.3 to
> 5.9 minimum carbs but more than South Beach

Hi. aha..42 years like me! It is the first time I hear, that
it is possible to exceed the used-by date of the insulin for
years. When in 2001 I found the little stickers on the
packages of my Novo Nordisk insulins with the notice, that
this insulin will no more be available after 31.12.2001 (
"go and ask your doctor"), I went in panic and I got a lot
of the last insulin. I used it still one year longer then
the used-by date. My first contact to Dr. Teuscher was in
the 80th when I noticed how human insulin was pushed to
market. I got important informations, articles from him for
my petition to the EU parliament. He has the courage to
publish his knowlege about risks of genetically engineered
insulin ( http://www.insulin.ch ) and he fights for the
availability of animal insulin. In Switzerland he was very
succesful. Is Iletin II produced in the US? Sabine
 
Sabine Hancl wrote:

> It is the first time I hear, that it is possible to exceed
> the used-by date of the insulin for years.

synthetic "human" insulin lasts close to 100 years with good
refridgeration and 5% potency loss (same is true for pork
and beef):

Jens Brange's '87 "Galenics of Insulin" has Table 16/p.59
time of storage of insulin preparations at various
temperatures until biological potency is reduced by 2% and
5% respectively

i believe that these are all (?) "human" insulins as beef
and pork appear (to me) to be either named directly or
ref'd as "monocomponent" (if i'm wrong about this, chances
are someone will say so. :)) another question is what
brands were used for the SL and L and UL? afaik, Actrapid
and Rapitard are Novo. one other point worth mentioning is
that prior to '87 Novo's "human" insulin was semi-synthetic
and not rDNA

Insulin-prep 4° C 15° C 25° C 40° C Actrapid 36 / 92 yrs
5 / 13 yrs 12 / 31 months 5 / 14 weeks Semilente 45 / 115
yrs 4 / 11 yrs 7 / 18 months 2 / 5 weeks Lente 36 / 91
yrs 3 / 9 yrs 5 / 14 months 1 / 4 weeks Rapitard 22 / 55
yrs 3 / 8 yrs 7 / 17 months 3 / 7 weeks Ultralente 19 /
48 yrs 2 / 5 yrs 4 / 10 months 1 / 3 weeks

although UL (UltraLente) looks "weakest" here, another chart
in the book shows a similar table specific to "breakdown
"toxins"," and in that table the protamine containing
insulins (NPH and PZI) look "bad" (relatively speaking :))
compared to the other insulins (i think "Rapitard" (above)
is a.k.a. NPH)

worth noting is that at 40C (slightly above body
temperature), Actrapid (aka "human"-Regular), lasts for 14
weeks with only 5% potency loss (zowie!)

finally, toxin build-up (due to age/temperature) have
only been a very minor issue with insulin over the 80+
years of insulin (at least with regard to beef and pork
and "human" insulins)

finally, it is likely that acidic insulins have a very short
shelf life, especially Lantus

bill t1 since '57
 
willbill <[email protected]> wrote
> synthetic "human" insulin lasts close to 100 years with
> good refridgeration and 5% potency loss (same is true for
> pork and beef):

Thank you for your important and interesting
informations! Sabine
 
This is a multi-part message in MIME format.
--------------33A88966E32608155ED51670
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 7bit

Hi Sabine,

They say they produce it in the US, but I'll bet the
crystals come from Nobel in Netherlands and it's farmed out
to anybody from Novo, to their new acquisition in Brazil, or
some Hoosier(Indiana,US) subcontractor.

A lot of people complain how hard pork is to obtain, but I
have script from my physician and hit Blue Cross up for two
vials every three weeks. Walgreens(the big pharmacy chain in
US) has no trouble obtaining the Regular(neutral).

I understand panic. I was cruising along real well until
March 2000 when I couldn't obtain Iletin I(beef/pork). You
can understand the feeling of alone and vulnerable. There's
a meeting of IDDT in Birmingham, UK on 09October2004. It's
worth it if can attend.
Dr. Tuescher has been at the last two. There's two
physicians on the board of IDDT who understand this. Dr.
Matt Helm is also a T1.

But I have a Baxter Revco bloodbank fridge set at 4 degrees
centigrade which I bought on E-bay for $500, and a few
vials. I had the house wired for my Generac 240 volt
generator.

I'm going to post a .pdf of the reference on stabilty at
temperature, by Jens Brange. He was the head research guy at
Novo. He's a hired gun now at http://www.brange.com

I KNOW THIS ISN'T A BINARY GROUP-BUT THIS IS IMPORTANT!

all the best,

BGN

Sabine Hancl wrote:
>
> > T1 since 1962(42years) 2x HypurinBovine/Lente mixed with
> > LillyIletinIIPork/Regular last A1C 5.7 on a normal 4.3
> > to 5.9 minimum carbs but more than South Beach
>
> Hi. aha..42 years like me! It is the first time I hear,
> that it is possible to exceed the used-by date of the
> insulin for years. When in 2001 I found the little
> stickers on the packages of my Novo Nordisk insulins with
> the notice, that this insulin will no more be available
> after 31.12.2001 ( "go and ask your doctor"), I went in
> panic and I got a lot of the last insulin. I used it still
> one year longer then the used-by date. My first contact to
> Dr. Teuscher was in the 80th when I noticed how human
> insulin was pushed to market. I got important
> informations, articles from him for my petition to the EU
> parliament. He has the courage to publish his knowlege
> about risks of genetically engineered insulin (
> http://www.insulin.ch ) and he fights for the availability
> of animal insulin. In Switzerland he was very succesful.
> Is Iletin II produced in the US? Sabine
--------------33A88966E32608155ED51670 Content-Type:
application/pdf; name="Jens Brange Galenics of Insulin Springer-
Verlag Berlin 1987.pdf" Content-Transfer-Encoding: base64
Content-Disposition: inline; filename="Jens Brange Galenics
of Insulin Springer-Verlag Berlin 1987.pdf"

JVBERi0xLjUNJeLjz9MNCjQgMCBvYmogPDwvTGluZWFyaXplZCAxL0wgMTI-
5NDI5L08gNy9F IDEyNTkwMi9OIDEvVCAxMjkzMDMvSCBbIDQxNiAxMThdP-
j4NZW5kb2JqDSAgICAgICAgICAg ICAgICAgDQp4cmVmDQo0IDYNCjAwMDA-
wMDAwMTYgMDAwMDAgbg0KMDAwMDAwMDUzNCAwMDAw MCBuDQowMDAwMDAwN-
DE2IDAwMDAwIG4NCjAwMDAwMDA1OTMgMDAwMDAgbg0KMDAwMDAwMDc4 NSA-
wMDAwMCBuDQowMDAwMDAwODkwIDAwMDAwIG4NCnRyYWlsZXINCjw8L1Npem-
UgMTAvUHJl diAxMjkyOTMvUm9vdCA1IDAgUi9JbmZvIDMgMCBSL0lEWzwy-
M2U4NGJlYmNiMmNlZDRkOGU4 MDk0OWMzZjk1ODAwZT48NTYwY2NkNzQyNT-
Q2NGI0NTliOTA3ZmI5MmM0ODMzYmY+XT4+DQpz dGFydHhyZWYNCjANCiUl-
RU9GDQogICAgICAgICAgICAgICAgDQo2IDAgb2JqPDwvTGVuZ3Ro IDQ2L0-
ZpbHRlci9GbGF0ZURlY29kZS9TIDM2Pj5zdHJlYW0NCnjaYmBgYGZgYLzNA-
CRe1jJg AhYGDiQeMxQzMGQyCDJoNzDY/E1gAAgwAJN2BRcNCmVuZHN0cmV-
hbQ1lbmRvYmoNNSAwIG9i ajw8L1BhZ2VzIDEgMCBSL1R5cGUvQ2F0YWxvZ-
y9NZXRhZGF0YSAyIDAgUj4+DWVuZG9iag03 IDAgb2JqPDwvQ29udGVudHM-
gOCAwIFIvVHlwZS9QYWdlL1BhcmVudCAxIDAgUi9Sb3RhdGUg MC9NZWRpY-
UJveFswLjAgMC4wIDI0NC44MDAwMDMgMzg0LjBdL0Nyb3BCb3hbMC4wIDAu-
MCAy NDQuODAwMDAzIDM4NC4wXS9SZXNvdXJjZXM8PC9YT2JqZWN0PDwvSW-
0wIDkgMCBSPj4vUHJv Y1NldFsvUERGL0ltYWdlQ10+Pj4+DWVuZG9iag04-
IDAgb2JqPDwvTGVuZ3RoIDM4L0ZpbHRl ci9GbGF0ZURlY29kZT4+c3RyZW-
FtDQpIiSrkMjIx0bNQMABCYwsTMJ2cy6XvmWug4JLPFcgF EGAAb6EGwg0K-
ZW5kc3RyZWFtDWVuZG9iag05IDAgb2JqPDwvTGVuZ3RoIDEyNDg0OC9GaWx0
ZXIvRENURGVjb2RlL1dpZHRoIDUxMC9IZWlnaHQgODAwL0JpdHNQZXJDb21-
wb25lbnQgOC9D b2xvclNwYWNlL0RldmljZVJHQi9UeXBlL1hPYmplY3QvT-
mFtZS9YL1N1YnR5cGUvSW1hZ2U+ PnN0cmVhbQ0K/9j/4AAQSkZJRgABAQE-
AlgCWAAD/4AAQSkZJRgABAQEAlgCWAAD/2wBDAAgG BgcGBQgHBwcJCQgKD-
BQNDAsLDBkSEw8UHRofHh0aHBwgJC4nICIsIxwcKDcpLDAxNDQ0Hyc5 PTg-
yPC4zNDL/2wBDAQkJCQwLDBgNDRgyIRwhMjIyMjIyMjIyMjIyMjIyMjIyMj-
IyMjIyMjIy MjIyMjIyMjIyMjIyMjIyMjIyMjIyMjL/wAARCAMgAf4DASIA-
AhEBAxEB/8QAHwAAAQUBAQEB AQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtR-
AAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEG E1FhByJxFDKBkaEII0Kx-
wRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpT VFVWV1-
hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipq-
rKztLW2 t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb-
3+Pn6/8QAHwEAAwEBAQEB

UQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg-
5OkNERUZHSElK U1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKk-
pOUlZaXmJmaoqOkpaanqKmqsrO0 tba3uLm6wsPExcbHyMnK0tPU1dbX2Nn-
a4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEA PwD3egUtFZjE70Dml-
FJRYAoFHakzTAU0UGilYBRRnmmjilosAvejFJQDTEKaByaKT86BoWlp B6U-
UALikVQowMkZzyc0v6UfyoAKKT60vWgQUYpaKAE/Gjv60dRSjigYhFGewpT-
0pKACgUlKK ACjvRR3pAJRRRQAnHNHajH1peg4osMQd6KUd6QnmgQYoxRmk-
FFgCkNOFBoAB0oo7UnfrQCF9 aMUHml5wKAEHSjvQKOhoAUUUD8aP1oATr0-
oxQaX1oGGOKKOlFArjelC04ikx6UDE6UmOKXGD RRYBO9LSYxTsdeaLAJ2o-
/CjoaKQrielHegUZp2GLSjr6mkxijPPtSAd2ooAFFWIQYyazPEMs 1v4d1K-
e2naCaK1keOVQCVYKSDyCP0rUx71XvrKHULGeyuAzQTxmOQKxUlSMHkcihA-
eXWnjS+ itJY9Rvr9h9ksLlW2Rxz75ZAj7BgK0WdgJwSNx9sdZceLoZJY7O-
MXEAvJriyt7xduBNGG3DB zjlGxuHJU8dM2JPAfh6ZNs1m8hEUcKs88hZY4-
3DoobOQNyqcDrgZzVr/AIRbSPtDTiBt5kkm X9621JHBDuq5wrEE8j+8fU1-
WhOtjAtfHkNrpdq14lxO0NpZve3CgYRp/lU4/i+brjpmoNd+I dtFZapCkG-
oRmGC4f7RbGPeghk8tzhjwd3TIORzXQDwVoSgD7IxXyoYmVpWKyLCcxBxn5-
tp9a xbX4fPIb+HVrxLizvGla5SF5UNxvYt8w34XGf4fzAyCtBmmPGCSLcT-
W1hPcWkEssEk6MqgSR 8MCGIwM5Gfb05qJfEEup3uiXNrNLDbyX9xZzwjay-
SbEl53YzjdHkYI4PI9LUngfQpftAa2l2 zyGZ41uHVPMPVwoOAx9R7+tWLf-
wvp9vLBJGk4MNw90ga5dgJHDBjye+5vzp6BqYXi7WtT0vV Edrie10g24UX-
Nsiv5FwWOGnBBxFtAG4f7We2J7PxhcSTayLi1QR2Wo/Y4iJQoYeUr7mJ6cse
nqBW3f8AhvTtSmuZblJWNzbrbTqJmVZYgWO1gDjHzt+dQv4R0l7qW5EMySy-
XX2xjHcOv73Z5 e4AHjK8HHWloLU5W58dXNp4gn1BIbu60b+wYdSNuvlqYV-
Z33PyRk7VHGTVi38RTX15Hc2d5f /Zvt9xA8Mgi+ZRbmRdnHAGBtye5z2xv-
f8IXofkLD9mk8sWYsGUzud9uDkRtzyvJ/PHSnp4R0 iNyY4ZUzO9xhJ3Ub3-
TYxwD/d4x0FGgznNJ8dzNY3kws7m8tLHR7S/DFlNxN5iuW3AYXdtXoO +fU-
V1+m6vDqsDz24zEGULIGyHyqtkf8AfWPqDWYnhK20q3d/DyR2t6LaK1je4a-
SWPy4/uhl3 DdgFgDnPNaWi6Ja6Fo1pptpGqQ26bcIu0E5JY49ySfxo0DU0-
IySTkg4NPpoUAmnY7UgD8KKM 80UAA96KX1ooBCUopKUUAB6UgpT0pM4oBC-
9OlJnigc0dKAEzRmjrRQAZpO1FHFAwooHSlxxQ AgoxR3NGfwpAFA6Un60f-
hRYBR0oo7daKLAFIKd1FIPfpQAe9LSEdaXPSiwCDpSjrSDAFL34p gA96O1-
ApO1Kwhc0Z96Q9KMfpQMWgYpBS/WgApPWlzSYoAD+FN7U7H1pDQFwH50vrQ-
BRQAY56 0Cl7YpO9AHBeJ9Z1/TdekFsJdrWsv9mW8e2SO8nWJnKyfLvU/wB-
0KwB29ecVc8H+ILnVdT1W zaWe4trVbd0uJotjbpEyyEYHK4B/4HXQnR7Zr-
03hMrT87GeVmEZIwSoPC8en9TUljpltp0bp bIQJJDK5ZizOx6kseT0H5Cn-
oItj2oA9aX8aMUihR0opabmqEKOpo6Uo600tt5NAhSPlpozx7 U0yKTgOPX-
ilDcgd/SiwDsUcU3IJIzz3pxYDrQADvS9aTIHB4zRkDjpQAZpc0wSoSQHXP-
1pyk Mu5SCp6EUWAXNFKO9JnFAAOtHekdljQyOwVRySTxSg5AI5B54osAve-
ijGTRg0AIetOBpMUuM UrAHWikpCQq7mICjkk0wQ6gU0MCu4MNvXPanDkZH-
NAB2pCARg0pHFNLKv3iB9TQCCil5pKQB 9aM0EGjmgBPxoxRj2owaBh2pe1-
NPAJJwB3pe3SgApMdaXB9KKAE6GlHSjGM9hRRYQnWlxS44 pDwCTwPegBcc-
UUYytJzQAUdMUh6U4cd6BgBxxQODQBRQIBRQDQKACjtSH60pIwaOgwxQOlJS
9qBBQPrSc0inOQRQAvejqKKM0DAUUD8qKAQv0pPWlpPakISij3paBgKUgZp-
M0c9qAHUlL2pA aoQevFVr60hvrVoLiNZIiVYq3Q4IIz7ZAq13NVb++ttNs-
Zr28mSG2hQvJI54VR3oQLY8Z0Kd dE8MeLddgS3S6stduFt5XiLbY3aNcDH-
8JB4/hzgngVlax4t1m8vtI1ZJ4473TZdXhSRU3iTZ GvlhgOMtwOOucivbo-
9d0qZbfbfW4NzD58SGQBmjxndjPSo4PEOhzyJFDqtg7uyoiJcISzMNy gc9-
SORVCPILHxLq9h4y1sp5Nk2oy2glmnG2KGX7I7bST0zKAD+I6nI7Lxrcyz+-
G/Dt5cN5Vw +o2LuqOwUZdS/DbSQP8AaA/Cuxj1jTJrp7WG/s5LhAWaJJlL-
qAcEkZ7Gm/2/o/2dbk6nY/Z3 Yosv2hdrMOoznFAHl954h1ix+Kc813HHcW-
kdxbWsVvJGzGO3aN5GuIznHBU7jtJ6DNeq6fqN trWl29/Zyeba3EW+N9pX-
Kn2PIqOfX9Ht4Lyd9StClmubnEqsYhkj5gOnII+tSJrOlGMFdQs9 rMiKRM-
uCzDKKOepHT1ouBwthYaenjjxYkVvZotvZ2jwZiBWNlWUkgex25rLPizXrb-
w5b3Npd 2ECxabps32YWvAeWQxuvDDCqBnA6cdO/pY17RVjmk/tWy2Q4Ere-
euEySo3c8cgj8KmTUrCW/ lsEu7druNd0kAkUyKOOSvXuPzFArHnqeMNYkt-
pLZ9QsbedLq+giu7hNscjQuojDAd2VjwME4 4712ms6jc2Phu71GGEyTxW5-
lCBCecZ6dTjrjrx61fOp6bHMYHvbZJldIzGZVDB25VSPU84He o5Nd0iJLh-
m1K0xbxNNMBKpKIpIZiPQEEfWi47HA61qV/f6jplk90J9OXWrZFuU27bmNo-
XZkY Dg7W289PmXuua7HxBdz6N4ZZ9N+zW7QtDFGHG1FUuq7RxhTg4XPyg4-
zxmo5fFdsiiW2iiubZ mtQskU6Enz5NgJXqAOD7846Gr2ta1DosdnJcxjyL-
i4EDyM4VYgQx3NntxQBxx8V6jBp95qSz yNKumLLFbzxL97zZFZ9qfe2gKT-
tbBHTqKfP4g159STTbW/tfs8t6kMWpPCHDq1vJIV2hgMqy rz0+cDqDns4N-
Utbh4zBLbyWz25nE6TKRtzjIHp79Kgk16yMmlizaK7hv7hrdJ4JFZFZY3k6j
E/qyKVwOM1Lx3qFlqF/HBc20iw2mpOFlTG2W3ZdowPmxjdnP3sZGB1h/4TL-
Vyu0axpix3EzJ bTy7WEZEQZVlaMso3PuA6ZCYHLcd3eSaPqljqFtNeW5-
giBW7Mc+0xf7zKcr0/Squlf2Ta3Ae yuYrzz4S0t490sjlY+VHuB5hPHA-
z70XAuXN7cW2hTXqQGW4jtmlEK/xMFzt/PiuG1LV76+WS zN6lxY+dpci-
3caBQ5kuVEkR7H5V3Y7BsN794Nb0hraK5Gp2RglbZHJ567WbONoOcE03S-
9RS/ u9Stvsxiaxuvs7ZIO792kgYY9RIKAsU9f26T4M1JLCK0gjtrKQxR-
NCGiACn5dnHHbHvXMz+K NZh8ReQt5ZSWf9sw2IiWHDeXJbiTdu3dmOOn-
Y/h3EOp6fcXH2aG8tpZ9pby0lUttBKk49Mgj

cb1XGcEbtpGea5/SPEd3qUy6xcyWYubnR9PeYSRZjLfa5Q3GeCARz24r1pt-
R0wNNH9std8OG lXzVzHnoW9M0x9V0qOyF49/ZrabzH5xmXZu6bc5xnIP5U-
xHIaV4l1aXxfHZXF9ZzWslxdQCK KDaQI1VlO7cefmIPrWl4x1a/06TRY7O-
9trQXt99nlmmi3hV8qRsjkc5QfnXQQX2nzyFILq3d xIYsJIpO/BJX64BOP-
as/WbSxvNRsmvpRElgTerJ5yqFYAp8wPVdrtz05+lAHIWvibxRcQRyG ey8-
2KyurhoFtTuuvKlKKy5b5VkXBHH5g0q+JdZnWxa38QaUbW8vBElwkJcxobd-
5MMTtAYNH0 xn5hn39BS4tJbUXcc0L2+zcJlcFNvrn0rLu20XU7rTZm1SDd-
Bcs9ssc64kl2FWGP4vlduP8A a+lF0FmcdY+ONXmltI7x4LeZRaiaFl2bxJ-
M8ZcZOSGUK4A+7nkmrEXiLW00k3Nxq1pvnvp7O HbbbAnlmfaSxYj5vLQ/T-
gZLCuml8U6UniQ6OZrcvHbSXE0vnJiHayKVcZyv+sB59DWjNqWmQ xXEkt7-
apHbsFmZpVAjPYN6fjQBwE3iW9uLi9me+gaBvD8N1FBIitE8haTzAB/FwoH-
U4zWgfF WrPqkqQCNvK1VbL7Hs+byCinz89eCS2fu7RjrzXZC+sGuRbLdW5-
nKeaIhIu7Z/ex6e9ZWi+J bLXdS1WCzCyLYOkZnjkV0k3Lu+Ug9ulAHIaT4-
w8QXMK+ZdWM0k2kW98AieUEkaXY6biWGcev 8XoK7nRr+S/0O1vZN++SPcS-
6BT+IBI/L8KhsPEWn3V7fWUzw21zaztF5Ukq7pFVFcuB/dwwr SgvbK4ZUt-
7iCUsokURuGyvQNx296APM9P8balq1jqAmv4I0iWwuEnhQIQkkrLLkMThQF-
78jP Pt6VcPPJYyC0nQTNGfKlIyN2Plb3rMl8QpB4mg0a50ueKK7LpbXRCm-
OZ0Xey4B3DjdyRg7T7 Z0bvVdNsWRLy9trd3AKpLKqkjO3gE+pAouBwo8Xa-
5/ZumvdOljPcM9rIJolw1xFG/msrZwE8 wAc8kK2ByDTJ/Eur6nLdJDfaf9-
jj0GO/dGt/MWSRxIrITu6AqP5V6BJeWMckkM1zbrJEhldG kUFE/vEdh71F-
HqukyCLZf2bCd2ji2zKfMZeqrzyR6UAcunii/kv3t7YRItvcWkUcG0f6VFKF
3yp7Lubpkfumz14zbLxrqsqxwSXVp9s8nUBKjgJskhuFjiz/AHcoxJzxxnp-
mu8/tPSgszfbr MC3by5T5q/u2/utzwahGtaO2oWlmL22a4vIjNbqJAfNQY-
+ZfXr/P0oCxHoGpSalosV3J5gZj IpEqqGBV2XB2kqenUcHqOtah/haorWa-
O5jd1TaFkePH+6xX+lWeDjpSGNjcnGe/NG87j7U5d o6Yowpbrx6UARhzzQ-
XOMZqTCgHgYpqhTnj60CGb2A55pwc5+tKMN+FLtGc5oGM3EZ+tKWO09 Kfh-
falwpHTNAiIuwIHagucflTigznNKFX0FMBnmdc/lTWbPtUuFyaQgDGVzSGI-
eV25waaQVT qT0qRQDg0u0YNADHcovH51Hvb5vepyAfekCqM8UCIQ5+UY4p-
w++RnpTm2DHc0LtLZ6E0DJB7 0UdqUE1Iw5oox60tUhB61l+IdNfWfDmqaX-
HII3vLSW3V2GQpZCuf1rU9aguzcLaTG1EZuNje UJCQpbHGSO2aAWxxqeEd-
Ra6R7qDTpkVI2DM7lopEj2YUbcEEY+bgjc3BqjZeA9Ss9MtbYCwM kFrp8H-
mBiMm2mMjN9z+Kug8JS6kmk3UOqiX+0racpNvuPNRm2KwKNgYUgjjHBzWNH-
8Q79IIp bzRUh+1ofsYS637nEyQlX+UbRulTkbuM/SqFoZOmeEbzWbPWITC-
liy6vqEsUzoyu4lSSNflK jKfvA2QedoretPB9z9ssLi4sdLj8q7NxcJEzS-
eZ+4aLOWX5iSwPOMBQOetEnjHWrea1guNAS GRop57kG8B8uKJ0DMuFO7Ky-
KwB2ntxQ/jXVRaWzwaPBcXV/Es9jDHeDEqlGchm2/K3y/Q7uv BwgM6DwLr-
a3GoTvJYBrqxktQI2ZVBMjOp2hAFB3c45zk5YmtDXfC2s6ndrLb/YkRnspZ-
d8jZ DQStIQPl5yCBnjp0px8caiNUjtm0dFgN5HaPI10NytJCsiHaFOeTg8-
+4z21PBmtXev8Aha11 S+iiiluNzqsTEjbuOOophY5gfDu9i0vT41j06S4t-
r24nljYssc8crSfKWC5BUSY6EdfWtLQP CF9ouuJd+dbJa+Q8csUQYqz/AC-
BWjVv9VwvzAMQ2F9Kn1nxje6X4gutOg0yKe3s7AahPO1zs Ijy64VdvXKeo-
61Xu/G+raaIv7R0NbXdKUeV7rdEBuQIdyqSu7cwG4KMrjPINAC6t4S1W51/U
L+zktDb3j6fIRK7Ky/ZpvMIwFOdw79qrHwLqDXSSK9pEPK1ONjGSC32mTen-
8P8OADUDfFOe0 sIr/AFLRxBaXLXUVs8VzvZpYGcFWBVQqkIfmz/jWonjPU-
5Ll7EaTAmowRPPPDLeqq+WrAAo2 OpDA/MFxxnqCUBA3hLWJbqe5cWCPNHp-
yMqyuebaYyNzs53A4/Cug8Q6RPqlvYiFLd2tryO4M c5+RwucjOD6+lYh8R-
6jJqFnHNaoWl1eezh8q6ZF+SJyu8bfmB2njscHtUdr49vL61i8jTYvt jXB-
s2gNycR3SmQvEzbOyx5zjncvrmmBE/gW/Frcx2stpC0sUpVSpKK7XPnqhXH-
MeBtPTOTxz Vmbwdfz6wdT86OB5bpZZYopW2ootpYdy/KPnzLknA4VR2qs/-
izUrG5v9RubFo4orGynu7OW4 3C0DSXCzOpUMG2hFJA6hfXiuu0nUpNTsFu-
5YFiSR28na+/zIgx2SdONy4bHbNK4aHn+peENT 07QLK4ldXl0vT4rJfsaO-
zTbZomErKFJ+UR527W6t16GfTvCt7qGkySWkEdk0wvCZJmk3ySTM j7irRo-
wXcuCuBx0r0clQetLuX1ouBwWt+Ede1mK5/daPaG6triORbcsjCR1QBjKE3-
OPk+YYX OFBzt56XRtOu7G/1i4uPJC310twgjYttAhjjwcgd48/jWxuX1pu-
9SR81AHnGn+FpdbsJPLhj 08xXupMlwqFJmWVp0XgqMLiRWHP8K/hqT+ENS-
ubu51Bms4rmX+z8W8bN5RNvN5jMTt6sPlHy 8ADrXabkx14pQRQM4C88D6h-
dw6ik1vpjzTNN5Nw0kjPtkl8zaQVwoHtncQD8tXm8N6zBfvc2 0WmSwSTz+-
bZTMwjaOREGchPvAp6EEMw712RZcUblxQI5HRtMkfxbdXce+Kzt40R4DamJ-
HulX YZEz1Xy9qjHBz1+Wrev6BcatetIqxGJrQwMRO0Um7zEcEMoyMbcg+v-
auh3L60gdCODQBgWmi 38fg2bSLyeCe8kimj8zbtVtxbbuwOTgjJxycnHNY-
8Pgm8t7zTXWHT2gjtbeG4jLOoSSJtwkQ KMMf94D7qntg9wHX1o3Ln71FwP-
PB4H1mXTF0+aSw/d6ReaYLhGbfJ52zZIy7evyHd8xyWJ9q mh8KeIItdvNa-
xp/mzX0V0LYzOUZVtjAyltnXncDt7V3u5aTcvPPFFxnAXPgTUbn7bGE01RIm
62n+fNu3kCMosf3duV6gj5SVx3ra8PaHqNhq+t398lrH/aLQukdvIz7dkYQ-
5JVfSul3LjrRu XpnNAjj7nwjczaxNdtHZ+UdUj1FZsFplCxKmwDHcr1z91-
jxVnwZp01rp8txJvEUsp+yRyxGN 4rYMxjRlPORubrjggHpXThl55FGRk80-
XCxhNY6w/iMXckVk1qmUicysXjUgbsJtxuYgc7uB+ Oed8RaNcan4+WFLKO-
WObQZ7czTofLRmlXHzbSN2M8cd674sMnmjcgouFjzUfDbUItP1OwWa0 uFm-
t5Y7a8uS7TfPAIsMOnUA7ucgYx3Gj/wAIXfx3n7lNOa2nsbe2nWROYJImY+-
ZF8uCTuzzj BVT7V3QdcHmk3qOhouFjz/S/AmoWemadbXEOnPNZyWweYSSM-
Z0i3YLbh8p+b7o4GW55qXSfC 2r+HbWwuF+yzPYW+oIyIW58+ZZU2jbzjbt-
xx14rvN6+tGV9aLgUrDT10/TbWzjLvHBEsYeRs s2B1Y9ye5qyEbj0qXKc8-
ik3rxzmi4EYjOOaAjcU8Oo6kUoYZ60ARhXGeaegwCMYpQ4A6ijeu OWBoAj-
KP9OtBVuenapN6560hdQOtAxADsx3pNhIzTt6/3qcGT1pARlGyRQEP/wCqp-
NygdRQG X2piI9jZNJscdenpUu9fWjep70hiZIWoyp5qUOvYijcvqKEBFhm-
XgUoVs1JuUDqKTcp7igRH sbg9qcoxgelODp60blPSgY7NHOaTtSgc0hju1-
FGKMU0IKiubeG7tpLeeISQyKUdG6MD2qXHN QXYuWt2FpJEk/wDC0qFlH1A-
I/nQgGQWUNnaNBaRJEOoAHU+p7msLRfB9pZaM9hqUdtftL5iy v5JVWVm3F-
drM2OfQ84FXjF4kx/x/aX/4CSf/AByofK8Sb8G+0v2/0WT/AOOUxdC3b6Fp-
dm0L wWMMbQxtEhVeit94fjgZ9cD0qmnhPQBA1sukWogMol8sR4AYZwR6dT-
09T60pi8T4/wCPzTMf 9ekn/wAcpFi8S7/+P3TP/AWT/wCOUwLX/COaP5/n-
mwi83zVmzj+NRhW+oHA9uKZD4e0y1vLa e2tkga2aVkWJdozJ97/9X09KjE-
PiYD/j90z/AMBZP/jlDQeJuovdM9f+PWT/AOOUAXpdH0+a 7nu5bOJ554Ps-
0ruud8XPyH1HJ49zVSLwloUMMcUWlW6pHkqAvqVJz/eHyrwf7o9KPK8T/wDP
7pf/AICyf/HKUR+Juf8ATNL/APAWT/4ukBQ8O+DbbSNKmsr4W9+8sk7O7Qk-
KVlcuV2sWGOcc
dcCr3/CJaD5dqn9k22LUnyfk5XPXnvnA/IUpj8S4/wCPzS//AAFk/wDjlAi-
8S5/4/NL/APAW
T/45QMmHh/S/tovPsEP2gTeeJNvPmY27vrgn8z6mnXmhaXf209vd2EMsU8o-
mkVk+9IMAN9fl HPtVcR+JM83ul/8AgLJ/8coMfiXHF5pf/gLJ/wDF0C0-
Ir/wzDJbNBpbRaeZlWC4dYA5eAbvk APA+8cHBwSeDk1tQwJbW8UEKbY4-
1CIo7ADAFZXleIyf+P7S8/wDXrJ/8cpuzxLnm80z/AMBp
U/i6YG1/npRisPy/Ene907/wFk/+LoEfibJ/0vTD/wBu0n/xdKwG5j1FNGC-
QOtYu3xPn/j60
V/wHk/8Ai6Fj8Shx/pel49fs0n/xdFgNzHHSl7dKxdniT/n70v8A8B5P/i6-
AviY9LvSsf9e8
W/xdLUZsn6UfhWMy+J8f8fWlf+A8n/xdJs8T/wDP3pX/AIDyf/F0wNrB9KT-
HtWPs8Tf8/Wl5 /wCveT/4uo9nigMf9K0of9sJP/i6ANwj2oI5rB2eKcD-
/AEnS/wDvxJ/8XQV8UZP+k6WP+2En /wAXRYVze6Gm5FYQXxRj/j50v/v-
xJ/8AF0mzxRn/AI+tLx6/Z5P/AIuiwG+OQaMHFYcaeJ9p /wBK0v8A8B5-
P/i6eE8Tj/l60vH/XvJ/8XQNbGyBycik6Viuviftc6X9fs8n/AMXTNvij-
nbd6 Yfrbyf8AxdFhG9jmjHHTFYe3xPk7brS/xt5P/i6THiYZJutMA9fs-
8n/xdFgNylK1hbPEuf8A j50vr/zwk/8Ai6mC+Jef9K0v/wAB5P8A4ukM-
2AMjpxRj2rH2eJsf8fWlf+A8n/xdJs8TE/8A H3pWP+veT/4ugDXIwOcU-
uB6VVgW8+zYvXheXd1hQqMfQk1J84x19qAJgBjoKTgnFRjO3v1pf m3E8-
jpTsIkGMU0YI7GmLuPrinxr8p+tIBduaXse1KaO3NAxvFLiloFACEUADH-
FKaPpkUAG36 UhFLk0E0AIFHpS7fpRzSg8UrjGgCk2rzTvpSE9aBWEx7U-
uAOg/Kjv2p1FwCjnPHWiigY6j6U DpRTQgFVNQaZLCdrZ1SZY2KM6bgGx-
xkZGfzq3mq95A11aSwLM8LSIVEiYLLnuMgj8xQBy2ne N7aPQ9Om1Vna7-
nsobucwWz+XGsnAPfAzkde1aMni3TEnkQ+awjuFtmdUyqyM6oAfT5mUc+-
ue lZ0ngOFrBLNdXvkjWwjsMqsWWjRtyn7n3u1SXfgy1uJb+Y3lwlxd7C-
JY0jDRsjiRG+7821lG N2cDiqER3fjGOW6h+wzBbVHvILpngZmSSBewzy-
Ac/XtVqy8X6a7WsEkk0k0sVu5mFs6xnzch G9F3EYxnrVK18B21vC8f9q-
X0jSS3UzSOI8lp12ueF/Ee/tUsPgmGEIi6pd7Y47SMZSPpbNuT +HuSc/-
0oQHVbwdpHQ0vmD60gUcc9KFCMuVcMPUUtA1H+tApaPxoAYBnd9aNgpUP-
Bp1ADQqlu efxrjdR8Q6hD4tTSIZrW3kaeHybe4ibN3B8pmeOTcBuUFvl-
5Py99wrsxisDUPC0Oqagk93eX Elul3HeLbELhZEA27WxuAyoJAPr2JoA-
jsvFlldWnnNaXaSmW4VYBGXkZYZNjthewOP8AvoDr UkfjDR3mMULzT4t-
UvN8UDsvkurMjZAxzsbH5VCng/wAmYT2usXsEqy3DRsqxnYk773TBXkbw
GBOSNo7ZFRN4HtVS7S1vbu1jnsYbBEiKjyo4txQqcZz8zZzkHNNAW5fGW-
jw2Ul28kgWK4ktp I1jZnWREMjrgeiKW+lNi8b6BNqNpYJeD7RdFVjQow-
O5k8xVI7ErzzXMal4Bu7e0Fpp89xcQ3 GoPe3BBgR0ZovLwqmPZtYE5H5-
d66DSPCs9jeQ38uq3QkaKM3VpFsEMsyoE3/AHcjhV4UqDtH HakBPeeJr-
ax8QNpU8LpHHYSX8tyT8iKrKMY/E/kPWqsfj/QHtWuEmlkjjWZpDHA7bB-
EQJM4H bcD9Ktar4StdY1U6hLc3ETPZSWUkcZXDo5BzkjIIIBBHpVafwW-
15ZiC61u+nZrW4tZZWWINI swUN0UAEbVxgfXOaAJn8aaJF5wdrgPDdRW-
bx/Z5N/mSAFBtxn5gRUJ+IPhhY43fUETd95HVl aP5zH86nlfmUj8D2rM-
1zwVeNKtzp1zNNc3GqWN3cM+xRGsGF3KOP4VHHrWlD4Ds7S8hu7G/v LS-
Zi321omXN7ucyHfkfL8zOcptIDEDtgGXW8U6Z9llmEd2Y45HiLG2kALLv-
3YJHOPLbP4eoq onjvSib2QpMbGz06HUWulUsrRSbyMDrwEz+PtUt74RS-
70dbB9SuVRbma4ZwkZLeZv3KQVK4z ISOMjAqhafDyzh06aybULx4LjSU-
0qZTsG9EDqj528MBIw9Omc0CNi48V6ZbSPE32hpVnNr5c du7sZPK83aA-
o7pzT7LxLpWpapLptrcrJdRK7Mv8AusEf8mIB+tZ1l4Na1vY7uXWr25mW-
8F4x lSPDOIfJ/hUcbP5D3zoaX4eGlaheXEeoXUkFw7yJayFfLhZ23OV4-
3ctzyTjJxQGpqh/zpSwA JzzR5dN8vmgNRQ/PPpmjeKXZjNN2e+KAHqck-
4oY7RSKMA0FcjrSGIH680bx/9ek2YHFCKe/6 0xai7x60N93til2e/NG3-
5MUAAI6HrS/jTQnvxTvypDF/hPekzS/w0UIEJ2o9KU8dqXrQCGbg PakD-
jJ5pSuaQR89ecUxC7hjikQ5pQnHXvmlUYBpMBDS54NBpevFAxOtLzilo4-
oATFAGKWigB KSnUlACDiloFFIBPej1pe1FAMTFAzS/hSimAlA60vX1o6-
HtSGOFJQKXpTQhKxvFl9c6V4S1f UbN1S4tbOaeNiu4blQsOPwraqrqOn-
W+q6dc6feIXtrmNopUDFdysMEZHPSgDgT4i1kvDbprl oUuLu3jW8NupH-
7yJmaMDcBuG1SOv31zmqGreM9VtdK12WHU7Rb3TIple2ePMilJFVJNuPl-
Vl y3JOdwxjBr02CxtLa2it44UEcYG0EZ/H6+9V9V0XT9Z0+5sL22DW9y-
myUKSpYemRzVXEkef3 vjHVNNGoQSahbypG5Fre7ERZT5DOU64+Vgp45O-
9R2JqXUPFt6U1O+t9atUtbTS4L3bHbrKCz +apH3ucFFPUdeeK9FS1tkh-
SIQxlE5UFR+dAtbcMyi3iwV2kbR09KAPN4/F9zctpu/WIY0XXH tZmjeM-
gwmGR4wx6csAMjGccUzS/Flyvh+3hhu7SyK6XNdwGK3UR3EiyMNqjptGF-
yo+Y7xgjF em/ZoNu3yY8ZzjaMZpfs8G0L5EeF5A2jg0gPPW8W6xF4iii-
lurcQtrcOnNaGIblSS1Epy2eq scD6Hr29DbOB2pPIg3FzDHuzuzt5z61-
JgdKAItx6A96TcxH61IoGDxS4FMBqdT9awbnXNUt7 uSOHwvfzxqxCzJP-
bgOPUAyA8+9dCKy7rXbO21+w0Zkka5vFZlKplUCqT8x7Z2nA9j6UgM/8A
4SPWM8+EtRHv9otv/jlJ/wAJFrH/AEKOpYz/AM/Ft/8AHat33iXTtMa/N-
7uhgsY2lmlIBG1V VjgDn+MY45Oams9SnnmgWbS7iCO4GVdyp2/LnDAHj-
pTCxQbxHrAGP+EQ1L/wItv/AI5Sf8JB rBOT4R1Lp0+0W3/x2ukIFGOuK-
SCxzI8Qaxs/5FDU/wDwItv/AI7Th4h1gEf8UhqZ/wC3i2/+ O10aY2dKX-
AFAHOjxDrI/5k/U/wDwItv/AI7S/wDCQ6wBn/hENTP0uLb/AOO10XaseL-
xFZG/1 i1mD240qOOW4llwE2srNuBz0wp64pAVG8Q6xtP8AxR+p/wDgRb-
f/AB2mjxFrG0f8UfqZ/wC3
W1/+O1fstbS+0M6qLWWOEjdGGeNvMXswKsQBz3PHOagj8S2895Hp9pBJcXr-
QmZolZQI0DlNz MT0LA4xnOKYEI8Q6x/0J+p/+BFt/8doHiPVz/wAyfq-
g/7eLb/wCO1safeNfWxmktZ7Vw7oYp gNw2sRngkYOMj2IqyMUAc5/wk-
WsD/mT9U/8AAi1/+O0f8JFrB/5k/VB/28W3/wAdro/wpMCk FjnB4i1f-
n/ikNTH/AG3tv/jtH/CQ6v1Hg/U//Ai2/wDjtb8jiKJ5NrNtXcQq5J+g-
71zreMbe 3i1I39hdWUtj5LGKdox5iysVRg2/bgsCOSMY5pgP/wCEh1j-
r/wAIfqf/AIEW3/x2j/hItYx/ yJ+qf+BFt/8AHa0G1fy9NhvJrOWLzf-
8AlmzISvBOSwYqBgdc9wOtVovEcd7eXNrptnNdvahP tBBWMRsy7gnzE-
fNjBx2zyaAsRDxDq/8A0KGpn/t4tv8A47Sf8JDrGSP+EP1P/wACLb/47-
W7b TC4tYptjx+YgbY4wy5HQ+9S9TSGc9/wkOsf9Chqf/gRbf/HaQ+Id-
XA/5FDUz/wBvFt/8dros Yo7UCOdXxDrGP+RP1P8A8CLb/wCO0o8Q6wf-
+ZQ1P/wACLb/47W+zIkbSOwVVGSTxiuYtfHem 31i93ZwXMyrLcJt2qG-
2wfffBP3eRjv8AMOKYFk+IdXx/yJ+p/wDgRbf/AB2j/hIdX/6FHU//
AAItv/jtXZNctFispId08V4nmRSx/cK/Lg599wIHU846VUg8TLexXVxp-
9hcXdpbSyRPMhUbm QkNsBOWwQR+HGaAsaen3dxeWvnXFhNZSZIMMzIz-
D3yrEfrVrNL2opDWwnNHNKtHegBOTS80o waO1ADc0Hp1paX1oATGO9C-
/WkAxnFOHSgA70gpaQHrQAYpCfelpKAAUtHHFGOtIBAOfejpzT sZpPa-
mAgNL3xR6c5pRSAM0Drx6UUuc0DAdOKUUg6UdqaEHeloqG6uoLO3a4uZ-
VihTlnc4AoA cVPPJoC571lf8JVoGP8AkK23/fwUg8V+Hz/zFbb/AL+C-
mI18f7RpoA3tyay/+Eq0DHOq2v8A 38FRnxZoAdj/AGtbf9/BQBthc55-
NG33NYw8VaFt/5C1t/wB/BSf8JboOcf2ta5/66CmBs7ev zGlCkdzWT/-
wlfh//AKC1r/39FA8V+H+2rWv/AH9FJAagHB5zS49zWSPFWgDd/wATa0-
6/89RT v+Ep0Dp/atp/38FAGoBnua5668LtN4ks9Wi1O7jEVx50kOVKn-
92UwPlz6Z59atjxV4fz/wAh
W2/7+ilPirw//wBBa0/7+igA8S6DF4j8O3+jyzPCt1EU8xVyUPUHHfntU2n-
jVdsS3wtVKph3 gZm8xsehUbR+dQf8JX4fGf8AibWv/f0Ui+KdAxzq1p-
/3+WmBrgH1NLj3NZX/AAlOgD/mLWn/ AH9Wmf8ACV6AWb/ib2eAOf3wp-
IGa6g7etLj/AGjWOPFWgggf2vadP+eq0J4q0EnnWLP6ectA Gtg568Vg-
W2jX9pruv6nEbZ/t8cCwRu7AZjDD5jt4zu7Zq2fFPh/HGr2f/f5aQeKt-
AC8avZ5/ 67LQAaFoo0i0u1yFN1dSXLQxtmOIv1VOBxxuP+0zHvVN9Bu-
bTxZJr2mmJzdWq29zBM5QfISU ZWCn+8wIx6enNw+KdBZf+Qvaf9/lpo-
8VaCEwNXswR0/fLQCNK2W4EH+lOhlJJ/dLwozwOevH fv6DpUuD/eNZP-
/CV6AWA/tazxj/nstL/AMJb4ezj+17P/v8ALQBqkEdzSYPrWU3irQQwx-
q1n /wB/lpP+Eq0HG4avaf8Af5aA0NRt4RimC+PlDcDNc7ZaZrAt7k6h-
baXcXFyFE/72QpKOQRhk +VQOi89Tk5JJtnxZoOedWtOv/PVaX/hLNBX-
dnVbPHb98tAE2gaQui6Ja6aJC6wJtGTkLznav +yOgHYAVnWOh3ui6vq-
txpxgmtdSmF08czlGim2hWwQp3KQq8cYOfXi4nivQCvOrWf/f5aX/h
KvDxH/IXs8f9dlouxmnGsixqJJMvj5iq4BP0p2D/AHqyx4q8P5x/a9p/-
3+Wj/hK/D+D/AMTa
W/3/AC0gNXBz940gB/vGsr/hKtB3H/ia2mP+uy0g8WeH/wDoK2n/AH+WmIt-
6ppker6XPYTzS pFMAGMeMkZzjBBBB6EEciuNsPAF/psd6yaktxNcSX-
6jz+FWO4ZW3fKv3soue3XGK6b/hKtBH XVrQf9tVqT/hKfD5/wCYvaf-
9/loAsaXpkOk6JY6XA7tDZwJBGX5JVVCjPvxWPoGh6j4dtZ9M tXtpb-
E3EktvJIzB41kcuVK4+bDM2Dkdq0B4q8P8A/QWtP+/y0f8ACVaB/wBB-
a0/7/LQBqEEj 71G0/wB41FaXtrfW/n2k6TRHjejbh+dT0hjQGA6/jR-
tO7l6GOMHNAfLcU7MAwfWgAj+Kgv8A Lx16UqnKg0hCfN60ENj71ONL-
QMZhz/F+lKA2PvU6gEDmgLDMN/epCrYOHxStIM+vvTVf72fW mAoRuf-
mowwHXml3+3am+ZgLkYJpagLhvWl2tj71IJR6UvmckjlaADDH+Kghum-
79KBJnik3jn g5oEGD60oVs8tx6U0yYxj15FOViXPpRqMeOlJ/nmlox-
SGAPHWlBpBSgU0IWmkU7vxSUAhuBS ACnUCncBMDtTAoLtxUlNH+sag-
GBRSOmaNgHbGKdS0ANCilwMdKWjGDQIYg4bPrS4GelKvQ0o oGJjnig-
4HUilHWuL1K31KTxVdWthcSsjwrd5+0tthmRWVUK5+VWJjbb0ba+aEI-
7LCk8EUi7c n5l615Rcab4j/seSO0TxKLi4LDbPOAIZvJZc/K2SpbGD-
uC7vm9q0TYa7fXV7cyPrNu/9kW6w gOdguMOsp2BsE4ZDjg+nI4YHpA-
wR1pMLn3rI8K/bP+Edtvt0LQ3OW3K7s38bYPz/ADAEYIDc gHB6Vr4+-
fnPtikA1QmOcZpQFDetIo5B7Y6Uo47UAh2BSeWpIPpSr9wZrz022uLF-
rUFlc3l3D ZSsbeVLovJMspR2jHzD5kTeq5P8AEhznOAD0Fo1weQD60-
ixr5eMj3xXmOtReIotMsl0pNfeZ FWZXmfnZ9oDMjKG5YJwN5Y7eMEl-
iLmq2OstbajdW0+rLcNqO1I2MjQ/Z8bsbUO4KWBG5Pm5H VaAR6F5ag-
0FRn6VBpnnf2VZ/aInim8hPMjkfeyNt5Ut/ER61a5oAZj2o2DPT8KdS-
0hkflpmk 8pPUetR3oLWVwAZATG3+r+90/h968z02w8RWtrZvLJrrXM-
dvpsk6vLI4M6y4uR15Hl9vunry 1MR6iEAB+YUjbEQszqqjkk8V51Nb-
eK5g7I99HqSzXX2ohm8iS2Kv5PlDpv8A9VjGGzu3decu bRtfm8J3dg-
8esTytaaZO6zTOzGZJP9JCsW/uhflBwTnHNAz1K0vLW8NyIJQ5t5TDK-
MEFXABx z7EfnVjb1FefJY6tB4t+3WsWppHJrB85CzeUbY2oTcVztP7-
xV568Z6Vt+BYdSh0m4TVUufO8 /wCWS4kZjIuxRuCtkpyGyuSN24g7S-
KAOl8sbjxSeWpHSn96O1ILDfLBIz1pQo9QazvEGn3Oq +Hr+ysruS0u-
5YGWCdHKlJOqnI5xkc+1cKlp41NlqJENxFIwS9iRbppCqylVkgUsfvK-
qStjO1 WkXB4zQI9M2jBORVXTdQtNVs1vLKZZrcuyh1BHKsVYc/7SkV-
wdrYa4bmwUzeIPsTOJLZ2ZQ8 Tb9zLMC2dhXgbtxxuHB21m+H9P8AEF-
ppWqWtzbanbzE3DWEkW8xorzu2HjVhl/m3ZHO0gAhh y7Bc9ZPAozzW-
R4eF0ug2ovI5Ip9p3q8rSEfMcfM3zYx/e5HfmtMZH50AOIDcUgjAPBp-
FLH1z gUZbd3oAcqAUq4A45pwowKQxv6U7HBpMUp+lABR29qOnSjPGa-
EAwoCfSk2ZzzTcse56UAkE/ WmIeI+T3puweuKQs2eM9KTc3Tk0BoPC-
Y70bBzzxQPvrmm44bnvQND9gPem7Ac/NTgcDIHy0x c5z2akJiiMccn-
1+tOVAnSkjzj8aeO9AxaBjPXtRRznr+VIYo6UUg4pRTQhRTSaXvUF5L-
NBZz S29u1zMqkpCrhTI3ZcngUIBsF7a3UtzDBOkkltIIpgv8DbVbB/-
4Cyn8adJNDG8SSSojTNsjV jgu2CcD1OFJ/A1wUHhzxJos94tg8Mo1H-
TZEknRRGYrwbikrZYltxdtxHotMfw/dtr3h7U4dJ vYYra7aS6guLxZ-
SmYGjDqN5GN20nnJ5OKYj0XjPUcUzdiRh1rzO38La3B4aMccN82p3D3-
Hnv JfmTav73yiA0mAcOoyOh5IOKnuNPvdR8QzCFr6DUooLCcFrw+XA-
+9/M3xh9pyqYwAc/jmmkB 3E+sW1tpNzqk5kitbYSNK0kLqyqmdzbSM-
44P1HIq7vJwR0NeY3XhzxLN4eu9Ontbi6iltr+O CP7UrPHLJK7RM7M-
/I2FQOSV59a9NhVjGhIK/KMqcZH5UgRMO9ApaSgBq9D3pRQvQ/WloGK-
OD WSL7SbbXGslCRaheHe2ISPOKr3fGCwUDjOcVqqcVzGu6VqOqa3ZT-
2T3NsbQSqZHZPJYPEyhg ud28Nt5wMDd68iEbSatYPDd3AuVFvaFvPm-
IIRdud3zdDtwc46YqvH4i0l2mC3i4iEjO21gP3 f3+cYJXOCO1cf4d0-
O80PSLHRb1J1hu4be1kt55vNSSddzzFeW2oyI3HAPoCTV+z8N3Gna8bq
3iuZdPtnurhLd3j3STTHLKn+z94/MR1H4MDp9K1qw1qKaSxuPMEMnlS-
qyMjxtjO1lYAg4I6i ru47sVieGrSSI6heXGnT2l3eziebzXRtx2hFC-
7WPCqqjnGeTjmt3BycUg6DATgDrxTlJbr0o C8DmhRhs5oBC1mabJpN-
rdT6Vp0KwPCTJJHDbskas2GPzAbdx3A9c81p1xy6fNpmpajqumWN1
aG4jkWS3uJgYri5Z1EThVZtufmyeOGGRxwDOhXWbGW/hsEuFa5ngNxE-
mD80YIBb/AMeH51Hp eu6bqpnSwuo5mt9vmKMggMMq3PVWHRhwe1ZJ0-
a6g8YaNcxwySWVnpk9s825fvs0W0YznpG3b 0qbQ9Pvk17VdRmjkgs7-
1YWSC4EfmpIu5SMpn5NuzAyed3ryxI6Hfyc0qNuXNGzJNKF45pAID
kUb8DPUUBcUeWcYzxQAzed1Zp8RaWtlNefaC8MUpgby42Ylx1UKBk/g-
O1aZT0Ncta2+q6dpe rmDTJZLua/llt03RkbWbhz844A/hyCenHWgDa-
XXdNawtL77Wht7wZgkXLBwEZ+3+yrH8KhHi fRjpc2pG9VbWGb7PK7K-
ymOTcF2MpG5TkjgjuKz9HjFsIbWHTbqIabZtmF/L3uztxgq2zf+7L
Hn+NfU1jX/hvWZfBuuWMcTzy3epR3VskhjWXy/Mid/MIwucrJjn7u0e-
wBnoA6GkHelA/yaOm aSAaHwSG4oDgjigr85P86Ty+McfhTEJ5gClmI-
CgFiT2FUINe025sRexzOLdpVhV3hdNzMyqu AwBOSwGelTahbRzaXdQ-
zWrXkMkTI9um0GRT1Xkgc/WsHQtJm05obBvtC2q3MlxaxXUvmPFCI
1XYWyc/vHJHJ+XHpQB0Fpqdlf/bBa3KSfY5mgn6jZIACV59mH50+wvb-
bUrGG9s5hNbTIHjkX oy9iK5C38OaybbxNDGlvbm/1k3Uf2oeZHNDsQ-
YIVs8lOh7fWtrwZYanpnheystWMH2qFNhEI IAHYdTzSGbp70Y4opRQ-
AgHFApRQMZoABnHSgY9KBQOlACdaUdDxQeOtFAB+FKKTtS5oAQ0gH
FLmgfSgBKMGl70UAN4OKXApRRQACkpRQaAG4444paOKPrikADNHP1pQ-
KOKBgvSl9TSL0o59q aAWs/XLi/tdFvJ9MtVur+OFmghZtokfHAzV8V-
U1O3jutPlhmuHt0IBM0bBSmDnIJ47UCRzWn +NrPyJXurtZmEhiWGO3-
aKdXVdzo8bHII4+uRjPeV/HOjm7ittl40skkUKf6My5kkj8xF+bGC
VB69O+Ke3hOxvrkapDqVwb3zRIl9EYywATYV+7tKke3p6DDR4C0438d-
4bu9eWO5huhvlDZeK IxrkkZPyk5yeTTEQXniyGbS2vtJuR/x5TTos1-
ucExyKjgncMFTlce+e3Ml54v8OaZcahcyxv /o6yGa4hti3+rba6lh3-
B45xnBx0p8XgKwgsBZRX14sKwzwjlCds0gkf+H+8Pwpt14Gsby11O
xl1G/FnqDSSSwCRQqu/3yvy5GTk4zjLE4zTAsT+MbOF4IUtbkyy6imn-
mNlC7JGQSZPPTyzu4 +nFXdH8S6drkhSxaSRTEJkl2HZIhOMhv6HB6c-
VSl8IWNxcNcyXV0Zjfx6gpBUbZUiEQ/h6FB jFWtB8O23h+FILa7upL-
eFDHbwyuCsCE52jAGegwWyQO/WkBtc06koH1pDEU8H60tIv8AFS5p
9QDvXOXniKSPxfpujwJE0EpkS4lZuVcJvVVH0wSf9ofh0f0rCu/DmgX-
uvW19JbWa6pAxnV1j TzGONoY8ZOO3uBQhGda6/qLwayZbUJf23NrYy-
wmNvnLLFmTcysGIxlcYwc1dtdVupvF2o6PI IfKgs7e4jkCkMWdpFIP-
PT5P1p40mRbuHF+bp1ljN5JcFQ/loHZAAgUA+YQenTNT2um2Y8R3m
qQ3jNdz28cDxh1IVFLMpAxkffb86YGamuao/hH+0ILYS3YnkibyIGkV-
VSVlL+XuDNwvQHOTW 7p10t5YW91FMk6TRJIssa7VcEZ3AZOBVSz0UW-
umJa2ep3KIJnlMi+WzMWZiy8rjG5iema0LW CGytYbSBNkMMaxoB/Co-
GAKQEo/hz6UgI555pVIAApQQTgD8aGCAcoD0rmLDxT/aPi660tI4x
YxWS3MUzfelPmMpI/wBn5eD36jjFdR2rkpvBHh+bULu5srW0iupbcWc-
6QKqbY2Y7z8oyrlWY ZoGWYddvX8SaTpzxxCC90yS8YhTvWRWjGPpiT-
9K0dFv5r7+0FlCf6LePAmwHlQFIz7802bTb KXxJaan9sIu4LWSCOEM-
u1o2ZSxxjPVF79qs6dpsen/a2jlkc3U7TvvxwxAGBgdOBQJFwUCjr
RjFIYlLnrSUhYbiO9HUBao6l9tFoTYzW8Lg5aS4Quqr34DL/ADFXA2e-
oI+tUtWs4NT0i9sbq ZoraeJopmVgp2sMNz24zzR1AytK1DVLnT9Jkl-
W0W5vEa4uCkbKvl7fl2gnIbLR5yem72rKi8 bXA8D6Pr90kcP2zPntH-
E0ixDa7Z2g5I+UZPYZJ4GR0VtCsl+92LmL7M8S29oiEHaRuZyp9/l
GP8ApnVSy8K2FjoWnWFtezfZ9P3eVKWRjtKspDfLtPDHtTA27OSSa0h-
lmVVkeNWdVbcASOcH vU2M1BY20VnZQWsH+phjWNMnPygYFWM5zSATH-
PWjoKTeNxFLkY60WAhuxc/ZZPshjE54Uygl Rz1IHX6cZ9q5/StV1S7-
tMzJZvdLqDWkdxErCKWNWy7AE5B2q64yRuXuK3L23+32U9otzNbec
hTzoCFdfdSQcGqFjpv2E2pbUJLm2jDeW03ljax2ogXaqjpuH/AqYiPR-
NWvL7VNRtr1fs7wnd HbvAVfyyzBX37irg7f4cY71u9az7HTVtLiWSS-
9lvLoxrG0k2wPsBYj7qgdSe1aIpDAijmk3c GlznHNAIQGlHWgEY60B-
ucZFAB60CjIC5PSgdPWgBDR60tHSgBMcUo4pQfSjjFACUA+tBOKaG
U5oAdTeaXIpCcDjFADv50nagGkDZJBpDHdqTPWijNMQnal5zSZGQD3p-
d3zYpALSjrSdBRQMQ DilxzSDNOz7U0AVXvHSOzmeVgqBDuYnAxVjqa-
iuHeOCR4o1kdVJVS20H2zQI86g8Sf2P8MtA g0+dGvVsrRJ2C7jaxfu-
0kkYYONobuPfBANU9Z8Ra/Y6PJc2muR3L2ti9yrx26lbpln2qDxyC

aU27tu7Gc9duD9OaYHG3ur39lf6xH/b0kCzaqkaSTBNttCbVHVh8h2qZPky-
2R/wI5rt9FkuL jSbaW6nSeZolLyxxmNZD/eCnkA9cVVu/FOkWdv8AbHv7M-
2QtWujKtwpJTcqgqv8AEpJxn1wO 9Xk1bTnvI4EvrYzTrvijEq5dcE5A78A-
n8DQhFwLwKXZ82ax7nxXolvpl3fJqljKlsuXxcrjc VLKpOeMgcVb0LVBrW-
gafqqxGJby2juBGTnbuUNjP40XGXqUCj3ozQIRe/wBaX8KRehNLnmgY mQG-
x0rifEEP/ABV2m32lpYz38PnJMir/AKQpMDFCzZ+5wo2nuynNdttG7d6VgX-
3iK4sfEFrp 8mlXJtrlmjju1ZSGkWMybdvXG1W59QRQI5Hwo9zceGDp13Ok-
51K1t3upkXZP58zMsyOc5LBQ eeCuPQCrOiWF7b+M/sRkt7u0tmvbia7Rm3-
bZ2BEMgxjII6bjxGOF4rYt/EX2lr+XVNDubW60 mJb2KFmSRnV0kVSu0kbj-
tkXH+NTw+LYJNe1DTVVPLsIvMu5RcJmI7d2Nn3sY74x1piJPBCwp 4Xjitv-
LEMdxcLGsf3VXznwBj2xXQbPmJrG8LeIf+Ek0dNSS18m2l5hbzkk3j32EgE-
HgjPWtj cQ3HQ0hgoOATzSruB5AApE/IYo5xnPPvQCH/AOc1wkH2LSvFepa-
vp0NpcWjadKZTYKDJ5yS5 KuQfndy5x0OVb1rugcrmsS11htQ1u50i60uaD-
yo1uond0YSKJCFOFOV5XIz1H0IAM4qXRdZs vEljp1pc21w0uoW99JOrt5l-
rFFEqSIw2kbWAKr8wJ8w8dTXp6fcGewrnrLxfb32q/YI7d1cS RxNuI3Bni-
My8d12jGfXPpmujQ5Wh7CQUUd6UdKQxpNMCHdu71J1OKD6UagMKk8YrD8VW-
EGoe H7mzutRTT4p2RfOcIwzuBClXBVgcYwetb4Oao6peXVjZmWz0+S+l3B-
REjqn4ksQKYjmvDqC8 sNJgvrO1geztXne3iVVjj3ExxuF/hDp5ny9ssO1c-
1p66m3wb0uzs7K5mt2sZftLwSojoFDYT DEHDHrjnCkd67XTNZN1a2OoLpc-
sdxqgLvGZFZkjRWKtnONp+XAHeT61Hb+LZr7wtY63pukXF wt0hk8oyJH5S-
DOWZmO3sOM9/agZsaOZH0ayaWNo38hNyNjKnaODir3b1qtp9017p1tdPC0Rm
iWQxseU3DOD9Ks0kBEIz82V60bDipOBS9qdxEE8UbQSrKFMRRg4b7pGOc+1-
cpoapP4M8NW8E Uc+yGOXyAwAPlJlfpiTy/ocV1lzM8FrJLFA87qvyxIQCx-
9OeKwNO8QjUbCPUhps6XUd1JYm3 LjOVl2yFSOGA2Fv+AkUBYzfCQ1JfFut-
nUNPuIZZra3kllkdCpfdLwoV2wMcD2Xnnr22Oaw9F
16/1PUJ7S90SXTnigSY+bPG5+ZmAHyk/3W/Kt0HntQCItjEHigrjHHOal-
J4o64ouBEqnHSl2 tuJ9hUgFHegBgQnGeAKcuQtO4pAaQBSetGaUng-
0DE5o6j0ozilHTpmgCModxP603YxB4qVm2 gk0wPnsRTFYbsJ/hz0o-
KNxxTlfj1o8z0FAaCBG9KNren404PnbSF+uD0FIYmxvpQFP4elPU4
UZPJ9aYGJbrxTEARjjPH9KcikNkilU5WlpMYvNBOD70UUhjV6U8Uxa-
d0poB1QXQlNtIIAhlK /IHOBn8KlrL8SyzQeGNVnt5Hjnjs5XjdTgq-
wQlT+dAjmtI8G6pounJb2U1ihl01bO6BjJVpE Takq/UH5lPBwPfPN-
6h4T1fSb/Trl0t7yS61izn8pBI6R+XbvG25iGwuQvzY79K7Ozmnn0T-
wv K09wz3G0zN5pzJmB3Of+BAGue0Lxhq8HhmC8uQt2sGizahMXfEk-
jK7cZx6L+tUItr8P7yK1v IYri2AurW+jbCnEcly6vtUY+4u3Hvkni-
rR8M62/ioaxNcWO1biO48pFZcYgaJl4+997IZsnt wBTrjxve2Taat-
3pkK/bTB/qrveUWaVY1JG0Hjdk5wOwJNVl8W31hdS6db2Fxql68t3M-
qCUKR FFOExuPH8fHT7tAhf+EN1GHR9OjtG01Lu1SeFwYz5ciyrjdk-
DIcfj1YfxV1PhvTZNF8M6ZpU 0iSSWdrHAXQYDbFC5x+Fcp/wsC6M3-
lHS1RXur20jc3G7MlvGz5YbR8p2+tTaR4w1W50vR2/s tr26m060u7-
popFTaJsgsAeONrNjj0GaBncjvQKQZx07UUgBT1HvRgZoUdfrS80AK-
vWudu9P1 yXxGl7E2nm0iG2JZfMLpwdxwONxzt3dh9SD0HeuS1LUtU-
Tx8NOsZmKPok08cDY2ecsqKrf8A j2KACz07XIJ0j1OOyne8u0eae2-
D/ACKm6TnceFyqoFH98n1zbOk6lLrEmoyRaestuk0doybs yB8bRLx-
wBjoCc9eKwdG1nWLmLUrMzXcN2llZxu10oJt7yUurn0OP3bbenp96q-
Vx45kvfEN3b WGqi2jTTL9YopYjlJojGFlbgk/8ALQgf3V9TimB2nh-
/RX0xr65mWCOa+lWaWG3z5cbBAvGcZ JxktgZ9K2Pl3Ed65fwVqd3q-
cWo/bjPBcQXWxtPnbfJajy0O1n/jycuG54fHaupK8k/pSARQN oJoA-
HY0iAheelEasG5FAIf0GK5ObRNTlvbzU5BbWd/LA9iktixYsruuyV9-
yj5kGSBz95uea6 ztgVzUMlzp2tXc82qzy6bb2kkl6bgKEjkyrJtIA-
xhN+R6FfxBlWTwhcjxVHqkc0SRxyxtHKp IlhhVNpt1XGDGxBY8jlj-
xnBHXL90dq5K6utXsdV0Sa/M39n3Aht28qb5luGDH94m35lJwOG4
9MdOtQ5UYoewkLSAil5NRjlmoAf+NJuHrUe4gcGhj8uMUWC5JvXpmq-
Or29ze6PeWthci3uZo mjjn/wCeRIxvHuM5FTqn3evWsfxRrMei6Q0-
jXS2rXEggSd13CMkE7vwVWx74osBPa2zx37RQ wqlrY2q29tyRuY8s-
D/shVjwfdvSszSfDWo6f8Prfw6ZrZrhIlt5JV3bfLL/OV77thOPfFQ-
+F tWm13w74ZuRfs8kll51zImAZJAiowbj+85P1UVkaD4l1bU9M8G2-
tzcyGTVLW5nublcKxaMDA 4GBywPH930zQB6OBilrJ8Oalcap4a0y/-
uVCzXNnFO4xj5mUE1pbic9+aBj+rdaB0JqNd/wAx 9qbljkHpRYQl4-
1z9imFisLXO392szEIT7kZx+VYmjaM2lTwweVFCjTTXpit8+VFIVVd-
i57Hc zducnFbciERuquVO04YdRXP6Pd3d94Y8OPNcSfaLsQtLKMBm-
wnmHt0Yrg+xNAGvp2nSWl5qV 1PKZJbufePSNFUKqL7cFv952rRFcz-
oVzfr4k1uxu5L0wwpC8BuvLbzA28M6legJX7p6bc/xV 0BLdc96LAS-
+tKWHtVf5tvvilJOMZzRYCcdKOnNQoS3ak3P684osFydWB70gIxkGo-
gT15pUJC UWC5KaM8HFRbiT16Zp27rQMk4o+lRljjqKNxwxHWkA9ul-
NAU96j3Njr3pquwABp2ETBF7Umx c4pm58nrg+1LuPHOaLBoPVV4ox-
yajLEHOaTLYIJ/CgZNxjB5+tIFAPFR7j36k80qszEdaBD1 G1eaUHP-
eo1Ld/wAaeOXyOlIY/PFHeijvSGNTp1p2cUxakFNAxR3prAMNpGQfW-
l71WvlvHs3W wmhiuuNjzxmRBzzlQyk8e9AkUrHw1pWmuz2tsyHYUQ-
GV2ESnqIwTiMey4qt/wh+gm0jtBp48 iOCS3VA7Y8t/vL15H8sn1qM-
23jP/AKC+i/8Agul/+PVG1v40B41bRf8AwXy//HqYizd+DtCv ZIJL-
mwDvBFHDG3mOCERt6DIPO1hkE+p9TSP4Q0KaTMtgspEzT5kdmO5vvd-
T91u69D3FQrB4z PTVtF/8ABfL/APHqTyfGIZv+Jrov/gvl/wDj1NA-
W08JaIk6TCxBdJpbhcyMQJJBtdsZ/iGQf qfWmweDdBt2sjFp4U2Uf-
lwZdzhQchTk/MAeQGzjtUKweMTz/AGrouP8AsHy//HqBb+Mv+gto
v/gBL/8AHqV2Gh0fOOlLg+9c2Lbxnk51bRP/AAXy/wDx2lFv4z/6CuiH6af-
L/wDHaAOhUHml Nc4lv4yw3/E10X/wXy//AB2lFv4y76pov/gBL/8AHaO-
oHRDrVKTR7KTVV1RoT9tWA24lDsCI ycleuOuD+A9Kyvs/jPP/ACFdE/8-
AACX/AOO0fZ/Gf/QU0XP/AF4S/wDx2gNC+miW1u0H2YGG OOf7RKB8xnb-
aQPMZsluSDk85ValuNOs7uYS3Nskj+TJb5Yf8s3271+h2L+VZf2bxmRzq-
ui/+ AEv/AMdpi2njJjltT0X0/wCPGX/47TQGvYaZaaTG6WkTAyvvkd3a-
R5GxgFmYlm4AHPYVe7Vz htvGeR/xNdF/8AZf/jtL9m8Y8j+1NFJ/68Zf-
/jtIDoYySvIpAzelc8tv4y2Af2pov/gDL/8A HaQ2/jIDA1TRf/AGX/47-
QwWx0mOKwovB2kW7zSW1u6PM2ZS8zyBgWDONrMR82MH6moUi8ZFf +Qno-
v/gDL/8AHacsHjI5zqmi/wDgDL/8doA0f7FsV1NtT8tzdHHJlcoDjbuCZ-
2hscZAzir65 21z7QeMcf8hLRf8AwBl/+O0gt/GO0f8AEy0b/wAApf8A4-
7QB0PWgCuf8jxjnjUtG/wDAKX/4 7TPsvjLr/aWjD/tyl/8AjtAHQFQTn-
FOHPaue+z+Mu+paKf8Atyl/+O0gt/GIbjUtF/8AAKX/ AOO0AdF0oIyrK-
eh61zv2fxjn/kJaL/4BS/8Ax2kFt4v/AOgjov8A4BS//HaANCx0Oz0+ST-
7O GSI20VrHGpIEcUe7aB7/ADHn6elRp4Y0iPSLfS4rUx2lscwokrq0fX-
OGzu6Ejr0OOlVPs3jH GP7S0X/wCl/+O0htvGWMDU9F/wDAKX/47QB0Ma-
JHGI0QKijaqgYAFOC4z7+tc6LfxjznUtFy fSyl/wDjtJ9n8Z4/5Cei/w-
DgFL/8doGdGODjFJx+Nc8Lbxj/ANBPRs/9eUv/AMdpPs3jAA/8 TLRv/A-
KX/wCO0CudA6CSFomztZdpwSDj2I5qhZaJaafHbQWgeO3toWhjiLs21WK-
9yc8bcD61 nfZvGJHOpaLn/ryl/wDjtJ9l8Y8/8TLRf/AKX/47QBqaZo9-
npETR2iSfMAC00zyvgdBuck4G Tx05q5uGOBXPm18ZbR/xM9GJ/wCvKX/-
47QLTxgP+YlowOev2KX/47QB0JdR9KUMpxiqllHer aol/LBLc87ngjKI-
eeMAkn9as7DwB+dADldSOvNG8Z7YpgjOPfpQFJPI6d6AJQRTC6hwh70Km
Dk0FAx3cZ96QClgM0v1FIUyKXbnqKYwBFLkUzy8cDAoCHGKQhxYAfjQCC-
KTac5pNhpgPJA4p pYdO9DLmmeWcg5ApDHIcAA+lLvX1FIqkYIpuwtkcf-
WgBxZMkZpN+33pPKJHUUGM+3rTEPDAj NODZNRKmO9PVdvJNIaH/AEpOp-
60dqBntSGNXpUgqNeKeKaBjh1oJxQBg0EZGOtAhuaQqDjNO xSCmLoJgL-
UZOXf8ApUpGaaB87cCgBuAMCnD/AFg/3acB170u2gAo6f4UvWkxQAing+-
tOpq8A 59aX60AKOtJQKWgAyKauc/jTqYG5xigB1NK8k048MPelPQ0AyO-
Pocn8qVBnmhOVxjpQGB5A/ GgEOAx7UoFNXOPWnCgYjD5TSLwKcRwaRR8-
goELTCx7YNOpNo9KAGl+KZu4B6GpDgfSk+QHNA MjDZYeuaAx5FSYT0xS-
EL2pgIrEKeKXfxwOKXaoHSlCjFIY3PPSk3cnmnbVHWl2qR7UCIgeWY HN-
Akb04qTYOmKQIuOgz60ARoSGAP86cWJ/KnbVxz1pVUEdjQCAN2prNtY0/-
aMZpp2EmgBm8n PpQJCFHNP2pg0mI8jAoBEYfH1p4kOeopVRDzilCDOQK-
AQwuTwaVWYJ06U4BcUoUFeOlADd/N
v1/LkUw7T3p+BtxnigY0Mec0M5A7U7aPwo2LikBGXJ7CkWQ7akwhpAijJxT-
EM8wkGlLMSv49 Kf5YP8NGwccUARl2DcdMUoYnJp+1c5wKXauelAyPzN-
ufegyEelOYISeBTflH8PtQITzC2Peg H58Cn7Vx0FG0elAySkxk0dqWp-
GMXkVIKiXpUgoQMdmkpR1NJ3xTEITigGikpgLnikX75o/Oo
8/O2KBEwxSjnvUOWUDcakU5XqaAHZoBpM5zSZoAF/ipaRejfWjPNAxe9Ga-
OvWloAQjcCASKa pp9NHegQMCcc4xRjtu7UtNwck9qABeFzSFtoxx9KW-
PO31pF5b8aAQ5AFWnCk6UooGI3Q0L90 UN92kT7goEL3qM554p/SmggZ-
oQAThPWgDgCkLnJpu7GPm/OgLkmM00fLwRTBISc54zRvxuH5 UWYDz16-
c0nOO9LHkpz1pCSDigY7OBSZ+XFAcc5ppbnIoAMHPFJyRgZoDkZ6n0pB-
L8p9aBDgC cZpMEDHNEbM3f8KfuHPNADlOV96ZjJ6GnBhim71A9aAF6K-
1AGNvFMMq+9L5q0WAcvSkAO6mi Tk+lOEg9DQAcj8qVAR9KQSg5HQ0KS-
UyTQCADAzR25zRvGBzQZAPU0DDnPtQN2KTzBQJRgUCH AfKR3pBnZ70e-
Z8pNIJKAF+YN3zSc8GjzOvGKQSZOKADacU3B96f5gyeOBRvU9jmgYwxt-
zQV5 6U7zODS7wfrQIIydvNOHWmg5A2/hRnEhU896Q0P5NOHWmilHWkM-
YvapBUSdKk4K4PehAx3rR 3ozVPUtSttKsXvLlmESEcIpYsSdqgDuSSA-
PrTEWzSCuUtNfuYta137XDevDFJapDbhFYx715 Py8bc8lmPHPakbxxB-
PJoX9nWz3EWpXk9oX3L8hiV92OcH5k4OcYyfSnYR1pHFR7f3jYrJg8S
2M+sR6WUuIriXzfLEqbd4jIDEDOcc8NjBxWLreu32lfECzt0W8u7J9Km-
meztkVjvWVBv5wej EYz9BmhAdnjil/KuctvGml3UiLAl06y2SX1vIEA-
E8bEABMn72WUbeMZHqKofEfUtR0vw/a3W nX81nI19BC7RRpISjuFPDK-
3ODxigDsqQV5/Za3q0N+9pqdxqP9nrqdvBYah9mSN7vcpLJIpU YUNxv-
VRntW/a+MLC6u7eEW17GtxdTWaSyRgJ50W/cn3s9I25xjjrnigLo6Bf4-
qdx7VyZ8f6L HD58qXUdo1o98lwUBRoVIBYYOerL8uM/MOKr3fir+0bn-
S/7Nlu7ULqsdtcxyRLiVGRm4bkEc dVP1pgdmXApQcjNY2va/baBbvdX-
cU7QRQyTyOiZCqmM5JIGTnhep5x0qre+NNMskmcwXkscF lHqEjRRAhY-
G3fNyR02Hjr6A0AdKPemAj1FcR438UyQaHqiaJcXK3li8ImlhRGEZcqd-
rbvVWz 8oOMitDxwdYtvDEmoaLdSw3FqyzOkaIxliB/eL8wPO3cR7gUB-
c6gnHFB+6a5FvElrLfS66mt Mnh6xsUlnVY1ZHZxvUk7dwIQqdo671/G-
vr3jJGsNa06ze5stWtNOkvFLohwqgEd2GfmGR1Ge 2RSsFzs4/u0oIHQ-
1z174qsNOi1IXMV0PsJhWUogPEvCsvPTP40kni6wgvZrZ4L3/AEe7ispp
PKGyOSTZs5zyD5idM4zzimB0lAJxzj8K43UPEc1zrGgjTXuUsptSa1lk-
2J5c21JMjn5uGQ8g AHH0ra1HUJhr+maPauENyktxNIeqxRFQQvuzOo5-
7bu9IDYb7p5pEHyjpXHDxFqqXHjdVRLpt IVDZQKmNxMHmbT3OWOKz/D-
3iS617Ub/RdM16O8U2UF3DqSxozRF2IdGUALnC5API3c5oA9C/ GmYHP-
NcZp6eINR0zUUTxKyrDeSRJqBtYwwWNQrgKRt/1nmKSey8dciPSvEup2-
2n+GrrWQrf2 rIbOQxrtAfDtFKFIyA6pyD03L0waAO2IGQM5BoEYB+9n-
0qK6jZ7aREmaJ2Q7ZEAypx1Gcj8x
Xn/gjV9R1fQ9D1C817Unu7z55YWso1gbG4sN3lD+FT0agD0Tyx0BP50CMVz-
48ZaX/oTN56Q3 6s1lKU+W4wu7C85GV5G4DNT6T4ms9Y0htWhjuILHyh-
Ms1yoQMmM7up4+tAG2vyjGaNuec1zF h430rUXlS2ju5HVI5V2xbg6u2-
1cFTgcnkNggcnAqe18YaZeJALV5JZp5poI4F27maIkSd8bR 65xyPWnY-
Df2c560m04+9XB3PjKbTfFl7LdC/fSE0WHUDB5Cq9vl3DMwOG6LyOT1r-
f8S+Ijon h5dVt4Ddh5oIlUMFH711UNz/AL3+eoQaG2UG3qaBGOxrF/4-
SmxN3f2RguVubMQF4yq/N5pwm 35ueeD9KpJ490nzMOl3Fb/bGsDcyxY-
jWdTt2E57kYzjHvQB1KrtOaNvvWDovi3TNfkMenPI6 +UJ0cqNroen0P-
ThsHnpRdeL9Msy7SvIbaO5FnJcqu6OOY8BWPXqQM4wCcE9aAN8Lz1FGz-
I69 65Dw5e6nrPiDWbma8nht7C/ks1tQkex0CJg5+9uySc574pLPxjZW-
1sA8mo3sl1qVxZxBoFDL IpY+XxgYG0gE+nNAHWlEyeaNiHGWxXOxeM9-
LuZNNihW5M2oRM8URj2sArhXyCeqk8gZOAT0p
3/CVaeDCjpco8uonTFyg4m2lvXpgdaYjoQi9M0KqgYzzXE6BrNxKulR32o-
3ks8l3fw5WFNk4 illVQ+BwQqcbcZxWvpXizT9YmtYraG8j+0xPNA88e-
0SKjBX75GCy9evbNAzoFjXnmnBcLgHi ufv/ABXZ6ZeXdtJa38slpAlz-
N5EO4LE28Bs5/wBhuOvHANV18eaM7XRiF1Ja2sEd1NdLD+6S F0aRXJz-
nG1T0FIDptoIxQ0YPciuUbx9o6ReYY7s5uIbcBIg25peExg4PPvkVYh8-
aadcPPCtv fLc28pinheHBhbZ5mXbO1VK9Duwc0Bc6Lyge9AirA/4S2z-
lh0t7S3vLkalbfaoPKi/5Z/Jkn JGMb1pyeKbM6rFpZS4W7mSaSKNkA8-
wRNhsZPHsWwCORRqGhv7Bz8x60gjGK4238Vw3SeHL25 mu7IajA9wIQq-
NG48rzDvbkgAcjHpVlvHWkxxQzTC6SK4s5L21Yxf8fEKKGYqM5BCkHBw-
eaYH UeWPWk8vDA1iaX4nstWvzZRR3MU32SO8UTIF3wuSFYcnuDwcGq8-
njXSIdTNk8kw2zNA8oTKI 4BJz3A4xuxtzxmkGh0nl+h5oCg5yeawofE-
9vPdRQLbXYaa0e7gyqjzI1KhsfNwfnXg461Hb+ LtPuhG8MN2wlsF1GP-
bFuLxtjaABzu5HFAHQ+Wp704Ko9DxXL3XiuCGwmurO2lneLUYbCdAy5
V3dFznODxIv+c4efElrZXl99rmu94uYbdIGjU4kkUbVTHXPUknjnoKAO-
lCr1pQoznqfeuWPj nS4JvsrpeC8F4ti9uIvnWVkLoOuMFRnOcVr6Hrl-
trtpJcWwlTyp5LeWOQYZJEbayn8R2pDNP FL+tGfxo70hkSYqUVClSrQ-
gY4dTWbr2jQa9o82nTyyxLKFxLEdrxsrBlZT6hgD+FaQ71keKd
b/4R3wzqGrCHzntoS6R9NzdFH5kU0Iw7nwTd3sVw13rrtdTTW8xdLZVjPkn-
5QyZ+YHuM4p0X gdoRZmLVpRLZ6jNfQyeQhx5u/evp/wAtGwe3HHrZv21-
Cw1XwtF/aMrJNdSQXSFV2znyJX3Hj I+ZeACBV62vZovE17pkkjSRtAl3-
bluqgsyun0BCkf7xHQCqEZWl+CX07V7e+bVpJxBcXEyho V3sspyVZurE-
HjPoAMd6u6xoEt5r1tq9lf/ZbuC3ktSTEJAY3ZWOBxhsqMHkexpmt+MbH-
w/Ps vba7KbYiZUjGweZJ5YGSRk55IHIHNMufF9na6teWbWN432We3t5Z-
lC+WrTkBD97JGWHQcUAZ zaCkuuaBpttY3ltaaGoZbpyvlzR7NqxA5yTu-
WNjkY+T3Fa3i7w2/ifTYLIXgtUjuI7gv5W8k odyjqO9ZWt+JHvXsX0pr-
1IYtZhs5p4ggjdhJtdWz823ORkd/atvxVrf/AAj3h+e/C75NyRRI ehkd-
wi59ssCfbNAIfrmiyazHpwW8SE2d3Hdt+63CQp/D14HNZMXhC+gFmf7Vh-
k+yajPqKqLP G5pd+5Pv8D96+P8AgPpyeIbPWLKSyvbHXrlWS4t7eOxKR-
lLkF1D7/l3biNxyCAoXOOtammah

I5VY7m8w56bcZPXGesPhfVZYdNF1r/2iazu0uTI9qo37QQFADDHDHJ5JPp0-
p2t+OLDw/PqcN 3Z3jGxtUvJDGEw8bMVyuWGcEcii48d6bayMjwXBctIsQG-
3EwRFZ2Rt2CBvVev3simAvivwo3
dcCr4/tA28H2W4tZYzCH3LKANy5+6wx154J9az5/BV5NY3Nn/AGzGRdaRHp-
crtZ5IVd/zDDjt

Mr7sYKk8/KcjqOPWgRjah4Anu/7RSLWBbxan5T3yLbA7pU2gPHlvkyFGQd-
1dl5avD5b4cY2t letcp4iur658QNpsM1/axRWH2oS2Txh9wk/2jg8LjBG-
Pm/GpNM8TGWfS7OG2ubi3uNJ+3LcT OvmPgJtDDP3ju57ZPpQMWHwDpdr4-
Gu/Cluzx2lyXDSYy+1mz17lVwoJ/uj6VU/4QSR9Nu4Lj Uo2uprF7COdLX-
aEjcguxXdlpGwCzFuoBx1ylj8SLM+HNP1G/tJUuruza9+zQsrN5a7dxXLc/
eAA+8ecCn+JfErXOjzNpBvUMFxbpLcQhAq7yjbGDc/dkXOB/F160gE1rwV-
d6012y6ytsl7Db rcqtqG3SRNuVly3yg88c9ufV8/hG+uZ79zqtvtvNQt7-
8j7GcqYdm1c+Z38qPJ/3vXjc13UpN E8O6jqcdv57WltJP5e7G7apb+lUr-
rxXa2TXMT21zLLZ2ou7qOIKxhjO7G7nk/K3yrk/L9MsV jMtPBd1ZXNpFb-
6wsel2V8by1tfsql4879yb88r+8bHGRW5qFhIviTS9Ygi80QRTWswB+YJKy
NuHrhoxx6MfSrX260Gk/2p5yNZCH7R5wbK+Xt3bh6jFctH4nu4fF9+88N+-
unw6Mt6to0as+f MYEqq5JYgYwT1oGbOn+H7rTdb17U0vYX/tRkdYjbkeU-
yIEXnd8wwBnp+FWNG0KHTPtNyzLLf 3jK9zOsezdhcKqj+FQOgyepPJJNY-
mp/ECCLQtUvbKykln0+7hs5oZHUbXkZAGyCcj94Px44r TufFllY6ha2Nz-
bXUclzdJZoxVdvmNH5n97kY43DIzxSAr33hm+k8P2WkadqsVnHDhrh2td/2
hupyAwwGbJYfxZweM5iudB1DUL3QItRvVuV066a/nnEPliRtrpGiqDx98k-
9fu/7Vb2rata6N
p/2y7LbC6RIqLuZ3dgqqB6kkVzOs+LCbW4tbS2uoL23vrOCeOQKGWOeVV3K-
d2CGUsAQeCPag Do4YL6PSGhmvUmvMPtuDDtXknblAewwOvOPeqHhTQX8-
N+GLTRZrqO7W1UpFKIfLO33G488nm mata3umeB9RSPU7prqG3mljupNh-
kXG5lX7uDj7ucdPeuevfHNlDoE9vqK6xYXKact55qInmS
q/KrPGSSMgkZVsHnpQBetfBkkUFjZy6ik1ppe7+zEe3+aI7Ci+Y2794FViB-
gL7k9a1tD0GPT fB8Hh28lW8hitvsrN5ezzI8bcEZPamXviezsPtRkine-
CxdEup027IS20/NznhWVjgHg1maVr U0GseIre8nmu9mrLa2cWF3DdAkm-
xegwMseewpiFh8I6qNAfS5vERmWPyltGNqoCJG6sFlAP7 zIUK3IyCeOa-
gj8A3NsI7mz1pYdQt7ye4tZzaKyos5zKjJuwwJ78YwMd86a+NNOEap9mv-
BdNe NY/ZWQLJ5yoZCOW242DcDnBBGOtUIfGulXV1YakJdQhtJdLnvVjd-
F8polZcs3Vtw4xjs1Axu peBLi/n1aX+2cf2hpY01jLBvZRuZmfO4cne/-
GABx6c6+s+Hm1bwmujfbBFNH5DLcCLI3xMrA 7M9CV6Z/Gkm8TxW9w1vN-
puoxv5qRZMI2/OrNu3527QFOTng49RWUPEEmpeL/AAu9hcyJp2o2 d3K8-
JC/M0ezaT7jce+KALC6ZHqPjiHULq0u0fTbcxNdOFjju2baV4B+YLuk6j-
gtWL4f8KXGp xalb6yCmmjXLm+itmgaN5D5haNvM3fd53Yx+Paus1rXod-
Du7C2ktbq5lv5WhgW3VTlwpbByR jgHn86p2HjbTdT8uG0t7t71nmV7Iq-
qyxmIhZN2W2jBZR15yMUCRL4W0G88P2gsJNUN5YwoIr ONogrRRjorN/G-
QMDPH0qrL4Iikubu3N3jR7u8F/NZ+X85m3BziTPCllViuPXBGaksvGNvf-
32 mm1t5Psd5Z3Nw8smEMJidEZWBPGCzZ+n1qvP8R9Fhhnma3vGjjhhnz-
GquGWRxGuMN13MuVPI yOKQzW8PaHLoraq8t5HcG/vGvPkh2bCwAK/eOR-
8orDg8EXVv9jZdXhL2+rTapk2nDNJuyuN/ AG9ufp6c6tv4ssbi6ubEWl-
1FewXK2rWz7d7OyeYu0htuNmW69jUa+MLM+Skthf2xmhuJlE8S xk+ScO-
uC33u47Ec9jQBlL4CnfSbXTLrV4pYYH3b0s/LkU+Z5m6Nt/wC7bkjI7Y4-
4qe78F3E+ qJcw6wsVnHqi6olv9lDN5mwqwL7uhznpxz14xua7q6aF4Zv-
dbuIW220BmMRIySBwvGR1wKzZ dfOiRW1rqFve3d5LZyXrtCqYwhXeoyw-
wF3rjP5k00xFaw8JajaS6bK2r2zizuLq42iyI3mdm JH+s4xvbH4VJo3h-
S90u60eQ6vBNHp0E0BX7HtMqyMrHnfwRsXt61NbeN9HmDM6XEEQ0/+0o5
ZVwJLfu64JI6jhsHkU3UfG2n6QuoC+tbuKWwtkvJYdql2hZioZcNtPIPf-
NAJFW90/Ur3xrqo t5Ps1lc6Zb20sklqXD4efcEbICsA465+90OKmsvA9-
pAus2pn/wCJXqVlDYC2VCHhjjQxrhyx ycE9R6Val8ZaZb3WoW0qyxyWd-
1DayFyqqWkQMuGLYxgjrj0qKTxxpttJsmt7pCrxrKNq5jLt gZUNkjoSV-
yMEGgDD8RaBrsOhaVbnUJNTuotVtHWUWnEUUcmdzKD8xHVjkZ9q1J/A7z-
alHqg1 QLfSXf2m8PkZim/deUqqhb5dq4wTu5yea6PVdUh0yOFpI5JHnm-
WCKOJdzMxz+HYkk9gazl8T RySG3TTr43QMgMDIqNiNlBbLMFKksuCDz+-
BwDK2ieFbrSX0RW1SOeDS7OSzCfZtrSK2zBzu4 IEadv73rxU03wJPYa7-
YanNrAuPsZuVAa2AklSUj7755YbR82OR2FWG8d6a1tb3NrZ3t1DPZz Xi-
mJV4SJlWQHcwwylgCPWp5PGOnC5EEVvcytJYpfW5QL/pEbMFAQFs7ssow-
cdRQBnQeBn8nR La61VJ7fSYpIEQW20yRtF5QUtu4IXv3P5Uh8B+ZpsVj-
PqvmLZ2M1hYOIMGKORAhZ/m+dgqgA jaOvHNa7eKLWP7TvtblfI1CHTpQ-
QnyySiPY33uV/ep79eKxdO8UrpFndLqUt3fTtqF1HAqop d1i52D7q5wO-
F6ntnmgVjT0jwxNpuuJqkmpRz7NMi04xrb7MrGxYNncefmNRp4WmXUb//-
AIm0 /wDZN9I00ljt+YSN97bIDkIepX1zzgkVOmv2dtPqXmyXTSrfR2qw-
SbeZGjQqsfqCGDc/7R4A qvN4206GIj7JevcJqC6dLAqLvjmfG3PzY2kE-
EMCaBlHStI1HTfE2nQXt5Nfwwabc26XH2URo gZ4dikjqxVGyfboO7F+H-
062Atz4gnVo9PTT4XjgVdqI4ZN3PzcKAwz8wLdM8dPomrwa5pqX1 rHJG-
vmPE8cygOjo5VlOCR95aqHxbYjWINLkt7mOe4+0GMumAwgOHOM7sH+Hj5-
u1AGevg24TT dRtl1SMSXV5BfRMloFSKWMxH7oblSYl4yOO/epLrwg981-
5Lc6kPtEl1b3dtJHb7fJkhGF3DJ 3A9xx36dnweOdKuNOsL2OOYQ6hKsN-
sXZAGYoZBk7sDhSuCc7uKsXXiywsbq0huobmL7TLDBG XUD55R8q9cnHA-
OM4JoEZ03gcz3kGotqUa6h/aMeoXEn2c7JGSMxqqru+VQpPcnNbPhfQ30-
C2 voJLpblrq9mvCyxeWFMjbiuMnvmqsPimzvr6fS1trtLhL5tPdcKCG8-
syb+G+5tHDfSrHhbU5 9Rtb6O7/AOPrT7ySykYfx7cFX+rIyk+5NJ7DN+-
gAZoHTilHWpKK6DgVMtRJ0FSrQgHAc5rK8 TaKniLw5f6S8hi+1QtGsgG-
drfwtjvg4rVHXrWZ4j1ZtC8P32qratdfZIjM0KttLKvLc/TJ/C mIgfTZ-
NUfSb27aa1nsJWl8ldpVn2NGc9fl2s2OnUUtrYSS+IbzVJ02IYVtbdN3O-
1WZmY+m4k YHovvgZ8Pio6hcT2UNpEZluYYcpdZBjkjMnmA7f7oPHqPpn-
K8J+JLn+z7awuba7uXliu5YLl 51ZphFNtI5PHDLgn36YpiNPxB4GtNfv-
bi5m1C7g8+GKFkj2EDypfMQjcpI+brjrxUlz4NhuZ tRlfUrzdfTW08hC-
x/K0BUpj5e5UZ/HpVLTPGYutPs49K0u6vnSwtLqeMzgyRxzD5fmb/AFjY
BJ56Drk4qj4b8Q3lrrWtWl3HcXFq+vvaRXEk+7yMxIyoFJztzn6bvrQFj-
YTwTBFLItvqV3FZ vfLqBtlVComDhyQSpO0sM49zitHxPoS+IdBm08sEc-
lJYn/uyIwdc+25Rn2zVDxB4w/4R+5uY pdOMiRWD3ySeaF81UZQ6qP7wD-
A++RUU3jiON3iitBNMZBDB5chKyt5QkYghc7VDKNwB5bHrQ Bdn0S8v9R-
GpjV9QsmeJU+yqsLCMfxAEqSCe5B7D0qXTNOn/t/U9ZukVDcpHbwR91ij-
3EFvdm kc/Tb3rKTx6s93FBFot8pNkl/P54WIwRFyrblY7srtY4xzjjOa-
teHvF41+6aIaZeW0bW4uoZ pIm2MhONrNjAfkHbz16nmgC5rHh6x1jUbG-
7vFZms94WMfclVgMq47jKq2PVRWb/whdtDZ6NF p17c2VxpKNHBcLtdmV-
wN4YMCDuwD9RWVeeI7rU/EXhG5tEmt9Lu7ydRJ5+PtKrC5G5B/CSoZ Tk-
/QU+6+IM0ukX93p2jTMY7IXtrNMGSGSPIHLbeGwQ23nPr1wwNmHwpaR6h-
f3Nzc3F2t9ZrZ 3Ec+0iRF3c5xnJ3tntz7Vb0HRn0S1W2fUru+jjRYoft-
G3Mca/dX5QMn/AGjycCs+bxj5OprZ DSZ5mjnit7poMv5LyBWHb5lAdSx-
4wD3waozfENYbDUtQPh+8NlY3n2JpfNj+aUTCIjbuzjcR zQBvXmjmfVZ-
tRW8ljkktfsuwIpCruLbhkdc+vHtVWw8MRWM+lvDeXBWwsfsIUhf3sfy4-
3cdR sHTFU4fHWdSezm0S4hMF/HY3TmVGETSgGIjB+YHcufTPektPFkMY-
cW2nX08k2rz2ISSdWIkR HY4LNgJ+7OB2/SgRHa+AYtPj0z7HrN9FcadA-
1rDOFj3G3OP3bArg/dBzjOfyq1ceDEke8EOq XlvbXjRSzwKEYNKm0bwW-
UkEhFz64z65rS/ES3isom/sq6lv2W4d7KL53XyJPLkwR947uF/ve 1R+J-
fEs95o1ydLt7hFtprdJ5/N8p42by327epwrruzjrjkg0DOn1Kyh1PSL3T-
JywhuoHgcoe drKVOPfmsWTwlG9zNdf2lcrPd2gtLx9q/v0G7BxjCsNzA-
H0Per3iDxAmhLGzWjTb0kcyFtka BFzhm7Meijv+FYeo6ldatrtrb2izR-
2jaW16hiuTE7PuTbnAP0xyPmPWgTOpk02xk0NtH+zhb J7c2vkpwFj27d-
o/DiudbwF9qS6+2a9qErz6f/Z/mKqIwj3Eg5C8tz171SsfiGzaBpNxc6a-
Zd SvrFr/7PbtkeUNuccdSWwF9uorasfFr6h4hn0q20a6K26wvPO7ooRZ-
UZl+UnP8OMdeaQyi/w 9tn0/VrWTU7o/wBpy28zssca7JItm0qAvT92vF-
S3fgZLzVFvpdWuvMS8hvlIjjyJEj8vrt6F c8dASTUk3jWIXWqWtvaebP-
p/mK6mUK25Y94JXqEPADc1Hovi651DRdGIskuNWvNOjv5beKUI qowHzZ-
PTcTwPY88ZoDQ2te0S31/SxY3LSR7ZY5o5Yzho5EbcrD6EVm3XhL7Xvmn-
1GVruSa3l klEagEQPvjQDHC7sn1+Y81UtfH8Gp3+n2uk6Vc3pvLVrrO5-
I/LVZVicMGP3lJOR7cZqxb+N7 RnvftVpNbLa2b3rK3zSCNCQ25ByrcZA-
54NAzoL+0TULC4s5twjuImicrwcMMHFcxqHgGz1Ww kt7+8nlkaz+wpOq-
qpjh3KxwMY3HauT7cYqFPiPaieW3m0y6EwS3ki2MrrIJ8+XyOQeGJ442n
rWnF4wth4bvNavbO6tI7N3SWKSI7mZSB8nTcrZGD79uaBCTeFIZrrUGN5-
MLbUtjXtvhdsjKq qSO67lVVb1A7daibwdF9svrxL6YXFxfJqEb7F/cyq-
nl8ccqU4IPqap614vnisdZ08Wb2urW9 ktwg80MDG7FA4YfxAg8eo7ir1-
3LeeHdMhkt1mvJLy/iUx3Vzv8gOyqyq2MkDtn+8fpQBieKv DdyI7M28N-
7fGS/N7eS28ULOziIxr+7kwu0DaO5G0dTyLkHg06rbWs2sTTKwsJ9Pa2C-
RoBDK3 Q7OFYKqD5Tjg1HD4hu9L8Ta3HNBdXVn9rsosmYMtsZlVeATnG5-
gcCtS08YRXuuxadFp900Us k0K3QQlFeIkMG/uglTg98e4ouwsQS+D57q-
Symu9evp7m0mWRJGVNrBQygGPbtJ+YndjOcegF O0/wZDp97pFz/aFxK2-
mJPHEHVMMspG4HAHTaMfjSXPieDS5dYnNlfTNb3lvbvH5qsCZAiqUB bA-
X5hnvnNR/8J5afY5pZLRreaHUTp0iXEqoiyhN/MnIAK4x/tMBQGgvi6x1-
C817w1LYpIBbX skssyoHESmF1BYE9MsB9M1JF4ItbW+h1OzvJ4dTVpml-
uSA3neawLhl9PlXGOmBVO4+IkNtp+ q3c2k3KNptnbXk0TMu7bMCQv+8u-
0g1HqOsfYNW1QXb3skH9pWMUSQz7PLMm33+7k/MB1zQBr R+EbaGSxeG5-
m228VxFKrqrfaFndXk3cdWZc8Y6mqUngZp9AOi3OuX09qgjSAOseYkjdX-
UZC/ MfkUZbJwPcmnDx5B/bX9nNpl0sf9pnSzcFlx53l+YOM5wR/SrniX-
xbb+GWRrmymkh/dl5BhQ AzhAFz95stkr6DNFwKs3glZb++1FNTnivbm5-
iu1lRF/cyxx+V8oI5BTIIPqai1fRH1K+0rTL izu7pLWeO/OqSyooDqx3-
JtXk7l+Xbt27W9q1bLWLy58U6npr2iJaWsMLxyiTLNv35yuOPu/5 zWDr-
fiaW+uNNfS1uFs49Zis5LiOXaHYPtdWXumcrn1HpzSDQ6fxDo8HiDw5f6-
PM5SO7haIuO q56H8Dg1ltoE+rfZrq8nltrmKwmsJIwikN5m3e4PuY1K+-
3UdqzptWlvTpVrbR3UcF5rF1aXP mXRWQbFnJCspyBujyMHoAO9Zeka5P-
aQvealdX0k1tq0ul2kQuCwuiqlcSKFx0QuWA65+lMDc j8AWHlQw3FzPP-
BHpJ0jYQozCdvOQPvfKOf0qe98E2mqw6j/al3NcXF9ZrYyTqAhWIMzDaB-
xu 3NnP6AcVFB44kupdNt7bw/fm4vreSfypSkRjEbqjg7j/ALWR6jGOtR-
r8Q7Y2d3frpV49lFYv fxzooxJGuCRk4AYg7gM8jPpigNCxa+DDbzajcv-
q1xPPqEkck/mwxlH2R+Xgrt5UgdKh0zwFB osqf2bqd7b2zRJFcW6lSsw-
XO3nGU4JHy44x6Corvx1cLoup3EGkNFeWltDcpHcSrtaOXcFbK 57q3y+-
3vWrr2s6hpmm2E9vZRSTXF5BbyI8uAiu4U4OOev9e2KLgWfEOhxa/Ywwt-
cTWs0EyXE FxDjdHIp4bkEHvkHqCap/wDCLul7BqCapc/2iqOktwyqwmV-
tuQVxhcbFxtxjnrk5gXxtDNrD WNtp9zcxpLLA88K5CSxqWZTngDIK7s/-
e4461Rh+IpuNIGpReH7sxSae2oRZmjG6NT8+eeCMj 65oGaB8E2iRxQ2l-
zNBFHYz2SqqKciZlaRzx94soPp14qwnhSwQaCJGeR9GTZBIwALLs24bHb
hW+qrVC98eiC6aG00W7uzHp6ak5V0XELE9Mty3ynilsPiBp+r3sMemWdx-
d20jpE1xHG2EZ41 kUkY6YZck4wT060C0Jbzwqt1fXUy6lcRQ3N5BfPAi-
oQZovLwclScERJx9aq3ngaC+0+8sZ9S uXt7qSZpoyibf3pUtgbeGUrlW-
6rk07TfHD6npv8AaEeg3Edq0philklTbuEjI2/BO1Rtzn3o tPGcmqx+G-
rzT7AfY9WMhlMsm14wqMcAAEHleue3vwwJX8GW0gmZrucyNdQ3sDnGYJY-
kWNSPU bVAIOc5b1ouPB9tPiU3Uy3LajFqM0wVczSIAqr04UBQMD0+tJZ-
+N4bp9OT+zJVN7eXNjjep2 SQhyfqDsb9Kr2fj1L/RbXU00a5ihvWVLLz-
GU+a2HY527iuAn60gN3QtGXQbGS0iuJJxLcS3B eQAENI5dugHG4msePw-
TCmqw6iNTuxJDNczRhVj4E5y6525POMHqAAKdp/jq21O/s7NNPntp5 4k-
maK8/cyAMzKQqN98qVJbHYqRnNWH1uJ/FGowyXHlWOi2sc1wAOGeTcfm9-
lRM4/2/YUDK0f gqBHvJjfSSzXzJ9q8yGNo5wqlRvjxtJOckjBJA7cVA/-
gC1MVvFFqV6kdtLaSxKQjENbhVX5m XOMKOOmcnvUPg7XrnVvGXiQXF4r-
W/l2r2tqJVYQKQ+4cE8/d3deTitTXLy90S31bWAPMhs7W a4CmU4bagKp-
txgcqx3fzzwCF021eXxJqGuzaXPbSxw/Y0yyk3KqzNvUAng/LjOD1yKu+-
GdIk 0qzvHuTuur68lvJu+wuflTPfaoVc/wCzVPTNIvrnQNPuJ9WuDqLe-
TcTyxzHy3+ZWdAn3dpGV 6dK6YUhhil4J/CgGg/SkMhTAxUw+72qCMY75-
zUq0IB/rSMoZdrDcDwR2NLTXBMZAYqSPvDqK aEc/pPgrRtFmhmsYpUkh-
tvsyl5S2V3MwY56sNzYPYEgcU2x8H2mnLYLb316psop4omYoTtlZ WfPy-
88qCKw9DuPEGp/C8Pp9yLjVJLi4TzrqYqSguZAcMAcNtG1eMDj0rc8LzT-
XnhNV8y7t7z EsTm7fz5IZlZlb5ujBWHB6EYpgRWfgex0+S2ewvL63MVp-
HZy7JBi4ijBCK/y9QCfmXafepof B9lb3Esq3N0Wm1H+0nBK4MoUL/d+7-
gDis2+m1KyutG0T7S9uup3kitKkzTPHGkTOVV3GcsV9 OATjoDWzYaCmn-
alHd2+pX7wLC6Na3FzJOrMxUh8uxII2kenzH8QCXWPDuna7Pp8t/G0hsZ-
Wl jAbhsqVIYd15Bx6qKoJ4K0620fTNPsri8s20wk2lzC6+bHkEMPmUhg-
QehHp6VtajB9r0+aD7 XLahxhpojtZV74Pbjv2rjLa38Ut4Mu4NNvftkh-
vmFlPcXGyZ7MEf8tNrDc2GAbH3WBzmgR0S +F7MarLqEk91LJLY/YZEkc-
FXjyzc8Zzlj3qTQfD8eg2yW8V9fXMEMXk28dxICsMfHygKoz0H LZOO/W-
odCu49V8Hwy6dc3JaaF1SS6YmRJMkEMfVWyOPTisO+vtTsdW0Hw2bpoRq-
stw7yxymV 4YokU+WsjjLFmOdxGQMgdAaANG08C2NnLp3k39+LfTZ3ns7-
YshSLcGUqDt3FcMwwTx2qaHwb aR6PPpLX+oS2T27WsMbyjFtEf4Uwozj-
AwX3EY+ub9hoq6ZetJDf3sluYiv2e4uGmAYkHcGYl u3c49Mc5tajC1zp-
80STzxFl+9bkCQ+yk9CfX+VAaGZB4XW31OS/i1bUUacxtdRh0CXDIAqsw
2/KcKoO3bkAZqvL4IsJdFvdJa6vPs95fG/lIZd3meYJOPl6bgKxtOn+1+C-
XvNQ1zWLRdKa6+ 0EsFnCo7bVkODuKoB069ea6PSbS+Twba2893NJqL2-
wZ5Zn+YSMMkbgOxOBx0FAaFeTwZaSXl 7dfbrxXu72C9lwUxviChAPl+-
78q/lToPB9pbSJJHe3m5NRk1EElP9a6srD7v3cO3FZl3Nqce taF4ca8-
+zRXy3M87pMzy+XEE2xJI3JJL5LdcA49a6DT9E/sy9EkOo3slt5RX7Pc-
ztKA2QdwZ iW7YwSR6Y5yAZi+CLSGeK5ttR1C3u4pJ2W5jaPeVmfzJEI-
KbSpbkcZHY1Lc+DLWaS8MeoX9v DeNG9xBG6ssjptAf5lYg4RQcHnFaW-
r6lJptukkMUUjNIEzLL5aIOfmZufTHA5JFcwPiHLd2O gTabo/2iXWBM-
qpJcCIRyRKxZSdpyMoRnHv7UAbeteGLbWr22uZru5he3jmiURFcMsi7W-
yGU8 4HBGD1pth4Xis7q2uPt95MYLP7GqSbMGPIOThRzwPyrEfxnPrug-
iTRbLM9xpRv5PMn8ryFYM qgMFYltytjjHynkcZ14NYTTPBdpqd3KCVs-
4mLSybd7sqhQWPqxHJ9aYina+AbWxXTvserajB Pp8JtoJlaMt5BIPlH-
KYK5UHOM+9bGnaBBp2sX+pR3FxJLerEkiyMCAIwQuOM/wAR6k1xnh3V
9c1nSfFyWGpWV9q0WpGO3bzsRRxlI/uY3YH39vB5HPeun8FaguoaBvaS-
8M8UskNwl24eSOVW Kuu4AAgEcEdRQMfc+ELG71ZdRuZp5pUWVIw23KL-
ICGUMF3beTgE8flUNh4LtdMWwezv7yO4s rQWSz/uyzwDBVGymDtxwcZ-
5PqaztWu9Z0e30yx+2RxS6pqUdp57SmUxJsdnZSw+82whVwQMj 6VtRe-
HvKkWSDV9SWNomVo3uWk+clSHBbOCNp+X7vzHilqBHp3hDTtK1a11Cza-
aI21m9osQI2 Mrv5jMeM7iwznNZh8GT6Rpk8mjahdz6hFZTW9stzIgVi-
5LDcwTdndznOfU1Z0/xLdap8PZta hSNb6OCcYY4QyRFlJ74BZSayPC+-
o6nZ6LYfZo5NS1e/sItQuYrvUHCKNoGUZlO1nPOzhRz07 gaEWg+C5J9-
O+x3UOqabbxNHJEJmtRKk0ZXZIhhXBxgj5859K6668O22oeH7rR9Tnub-
2K6GJp Znw7HjBG0ALjA+6AOPrWTZ+N5dWvdLj0jSjc299ai7M0k6xmN-
N6o4285Zd3T2NXda114r8aH p8AuNRmtZbja03lKka4Utv2t825lA4/L-
FADZ/CFndC7e7u7qa7urZLV7k7A4jViwAAXb1Jzx WlqWlpqVlFbSXE0-
bRyxyrNHt3bkYMDyCO3p3ritM1+8j8OaJITNLfN4YkvEnluDseRVhzvXn
LZYHcf8Aa9TWBDPfrB4Z+36rew2er6ZLqN/Kuoyb42jjQ+Yh25XhtxQf-
LnjHHIB6FJ4Rt5Zr +Zr+83Xs9vcS48v70O3Zj5P9hc1Pp3h5dMvJJoN-
RvjbSTSTizZ1MSyOSzEfLu5LE7S2MnpWB
b/EC6Nhf3Mnh+6EMEEc9vKQ6rMrNt2lnRQHGQcDcOeDUmoeOtTsHjgPhqW4-
u0VZbmG1Z5Ssb SMqlCseGbClsMV/GgZrXXhOC7fUHa9vFN7cQ3D7PL+V-
oipTblenyr1z0qP8A4Q2z8jUoPtVy Y9QumurhHEbKzMgQrtK424C8eoF-
U/wDhN7xdXS1l0TbanVP7Me4+0qSrFNysFxyOx54z3rT8 MatfatZXVxe-
wW8Wy9uII/KlLbljmePnIGPu/j7dKBWMib4baS9lPYxXl9Ba3FlBYzxxy-
KfMj izsyWUkHk9MVo3vhC1v3naa9vN01xb3LlSn3ocbP4emQM/Ss5vHF-
3FfRfaNCaPTn1E6c10tw rMkm7ahKAfdLEDOeCRVaL4kTS6Zf6jH4fu2t-
IbJr63nIdEmQH7rM6qA2MMAu4EZ5oA1W8E2J vTd/bLwP/aY1TGUx5wTZ-
/d+7t7U/xB4Os/Ed3JPc3d5Hvt1t2jidduFkEit8ynB3AdOuADnF U5vE-
8llqiza1YyWKQ2F5cny7nzEMUTRZJUDlsMPp8wGc0k3jz+zNr6xp4tori-
2FzZtDN5pmB dE2MNo2vmWP1HzHng0tQOgt9IW31aTURd3DPLBHDKjbNs-
mzdtY/LnPznpge1ZSeCrSGZhbX1 7BaG9F+LVChQS7t5wWUtgtzjOPTFY-
qeJNT0jW/El3q0KpHBaWLJAl00sKb5JUL52AqOm75ei ZrpLXX5JfC02s-
yWse+OKWURQXCyI6qWwVk4yGAB/GmA238K29vNbSC8u2NtfS36Z2cySBw-
wO F6fvH/P2qufBFgbSSJbu9SU6i2pRTq674J2Jyy/Lgj5iMMCMGsufx/-
qVr4Yj1y58PJDDLbm7 TdeqVaMRCTGdud5yVC47EkirOreOLiw+e20g3M-
P9lnUy7TrHiNcbl6H5sH88fWjUDZi8OxJq 9nqj315NcWsEkA8xlIdZGD-
MW+X1VemAMdKpQ+DLaLQ7rRP7S1F9Omt3tUgeRCIYmGNqnbngc DcWwOl-
Vdf8dHR7iaO305btbdbYzZl8tz57lE2LtO7kc8jGe9Qx+KprFL110ueWV-
tZFkY5LoN jcqbWXPRfmHyj/GgLmmfB9nJDexvd3bLd2Udk/KfKke7YV+-
Xr8zHnPWr99o66jpcNnPd3G+K WKZZ12h96MGU/d29R6VjL4zmbS7ORdO-
iTULm6ntPIe42xq8Pmbv3m3ofLOPl7/WrFt4ok1H4 ev4ktrMRSNZvcxQ-
zN0wGIyQPQZosBNa+F4bG6u5bW/vYorp2mktwybPNZcM/3c5PXGduecVW
g8D2VvpUOnRXl6LeHT5NOUbkz5Tnnnb97gc+1YWja5qenNpdlFYS397ql-
kL+UzaiWSPaUVtu 5cjIfdtHGeB3Na//AAm2LyxIsA2m6hdvY21ys2WaZ-
Sw+ZMYCsY3w249Bkc0AUovCt4PGUgP2
bA/sSPT/tG6PMhV3JU8ZHysOQB3ra03wfZaPePLpVzdWdrJsMllEy+SzKqo-
rcqWHyqvRgDj nNYdh4+1fUre2ltvDsAF4twLcPf7cvDIVYN8nyggZB5-
54x3robPxIl94Mi8RWtnJJ5toLlLY MobJGduScfjS1GU4fBdnb6PaaZ-
BeXqR2l79ticOu7eWZiD8u1huYnBHp6CnWHg6102z0y0tr u7EenStJA-
SykhWDAofl+7hj7+9WvDviH+221KJ4oUlsrgQsYJfMR8xq4ZWwP72Ona-
uTj1u8G va3qd350j2GprYWNvb3Emxw0Sna8aqc/eL7sFs8DhRl3FZG7-
D4HtLe/guYr++Atrya9hi3Js SSUMH/hyQd7dTxmnxeC7S30DTtJtry9-
hXTZPNtblHXzI2wy/3dp4Zhgg9ay5viFqFtBby3Wg C1aeC5ZUuJ2RjL-
CC2wAx9GX5lY46HI9dzw34lHiGIXMcUAtjbQzCSKUvh3XcUIKjBUbT/w-
AC HAoASfwlaXklm13cXc4tZo7iMSurESq27eG27lJPXaQMcYxTpdDA8-
Q3d59nintdSt1t7uN+c bN+0kHhgQ7Kf+A+9YP8AwsK+N1EiaChhl1Sb-
SUc3gyZ03YONv3TsOTnI9DWhB4zmuodPtoLC H+17xrlPszzkRIbdykp-
8wKTjcOPl5z2pDL2l+ENF0TVrrUNM06G2lulRHEUaqqqvZcAYz1Pr xW-
rcW0dxbzQ3KCSGZCkiHoyngiuWTxxqFybSCy0NHvLiC6ZopboIscsEqx-
yIW2nI3NwwHPHH PDLXxZe614g0m0ghjh03UdEbUGbeRMjFkAxxjjd+p-
PYAsRu6XoI0q1t7O31G9+xW6qkNuzqQ ir91d23cVHHVqtaTa3lrBOl3-
dyXJednjMhBKKei5Cr79vz61wPg7xlqVt4Nsnv7CW7f+yJL6 GQTmWa6-
MbAOGGOD8645bP6V2/hzWl13TPtqm2KFyFa2n81GHHfAIPYqRkYpMZrj-
8aUdetJ9a UDnjrSGV0+tTLzUCcgVMuaEBIO9MdSyEBypI4YdqcO9Y/i-
rUrnSPCmralZiNri0tJJ4xKCVJ VS3IH0poRWs/CaadoMWk2GrajbJFO-
06zq0fmfMzMynKYKksTyP5VsWNnFYWywRbioJYlzksx OWJPqSSa5t/E-
2qpYzmG0tLmewsku7sGUpv3BiFTg87VJyeMkD1Iuaj4phtvC1r4ggjeS-
1uEh lD7CfLjkx87KOcAHnH/16YF/WdFtNatY4ZzJG8UgmgnhfZJDIMg-
Mp9eSPQgkGs658N3s2k3N uNe1GS9kTZFduyI0PI5UIoXt1Iz1GRWSvj-
y9ubyG20vSk1Fkit5btrefcoWUsMxtjDbQpbnG e1PXx7JBHqg1C2hjn-
0y5nW5hics3kRxeb5qg4zkFPbLDmgWh0eqaS2q6K2myX9zB5iqsk9vt
V29eqkc9+KoReGbmGy8hPEus+b53m/aHkjZyu3bswU27e/TOe9ZJ8ZeI-
I7Oed/DqgB7UQu05 VJPOdUI+7nKll7YIp+seNNR8P20Ump6daLJ/o4l-
ihuN5JllKMV4yFX5TlgA27FAHW2dnBY2k VrbRhIYlCqBVTWdDtdat44-
5zLFLDKJoLiB9skMgBG5T9CRg5BBINZ3hoOms+KIjLLIseqLsE krPsz-
bQsQMngbmPHQZqjB43kxcw3UEEd7Y3Fwt5BG7MUhiTf5i5AyCGj9v3g9-
KANO70C+l0e 6tk12/N9Mu1LwsitHyD8qqoXt6ZPTPpo3+nz3unrbRaj-
c2kysrfaIAm/j2ZSMH6VgW/irVmj ma80UWqBodlxJKFi2v8AeJ3bWyv-
oB82RjviAeNNVutO0KfTtJtppdUeaILNctEEdFc/3CcHy z+lAI3m8PW-
b6RJpspkkimlWW4dwuZ23hm3cY+bGCMdDgYrWwMAVzukeJZdR8QXekzR-
W8Mtqr GaLzD5qn5drBSBuRsthh6DueOj9KAMnW/D9rrf2Z5JJre8tHM-
lrd27bZIGIwSucg5HBBBB9K qXnh6/l00xR69qBvGdGF2WRSqgg7dqrt-
xxzxk9M10I60GgDM1jRk1dbXN3cWsttcCeKW3K7g drKR8wIwVZh07+1-
Ydp8PrKxi0tLfU9RT+zZJ5bc7o2wZQwbOU5wGOPr3rr+poxQBxkPw5sbS
0sIbLVNRtpLS0ay8+Noy80DHOx8oV4PQgAjmulstLt7TSbbTGzcwwRrG-
DOAxYL03cYq9il7U Boc3F4QtrKHUF0q8uNOlvrz7Y81sI9ytgDaAVI2-
4XoR3Na+mabb6VafZrZTgu0ju3LSOzFmZ j3JJJq50oFIZna1odlr2n/-
ZL1G2q6yxyRsVeKRTlXVh0YHmq9vpd9p9u8h1G61S6C7YvtRjj C+52I-
PzwfbrW12pKYGDY+GYbHwgPD8U8iI0LJJPGBuZnyXcBsgEszH2zVaPwj-
Fb2+nR2eq3t vNY2v2JZ08svJDgYVsqV4wCCAP1NdMaYrYTkc0IRjWHh-
i007VrW+tZ5o4rWy+xRWvy+WEypz 93cWyo5zRrHhuDVtSttSiu7mxv7-
dGiFxaldzRt95GDKQQSAemQRxW0i43HpTMNnjOe+aAOWi 8B28NtZ26a-
rqHl2mnSabHnyz+6cKCfufe+RP++frmWHwTYq+imS7up4tJs3soo5Nmy-
WNlCtv +XnhVHGOn1rpTn3xTQTwBwcUAcvD4Egi0e50ttZ1WS3kCpD5s-
qsbeNWDBEyvTgDLZOB1q5qP hOO/1SHUBqV/azCFbe4Fu6qt1GCSA429-
izcrg/Ma3BuwetOjz3oA5d/BMMkrs2sajltSGpAf uuJANoX7n3cAce3-
WtTSNGj0d7xYbu4liuLiS4WKXbtiLszsFwM4LMx5zWky7WA696RAwbkUB
1OW0fwzcSXF1LqrTLC2pSXsNnuQx5JBRjtGcgjOM4zzSJ4As49IvdKj1-
XVFsriNoY4jKrC2i
c/MkYK9O3zZIHAIrq3yG4zTctz1zigDHu/DNrqF1FcXtzPPGtnNZSQsFCTR-
y7d+7C5ydq9CO lUz4H0+6sWs9Quru/iS3+ywecyhrePcrfKVUfNlI/mO-
T8g989Nggn8KaMjOAc80Ac9beD2hl ubl9f1Sa8nhhiad/KztidnXgIB/-
EwPHIJq5aeGLSw8MzaFbTSxwSpKrSLt3gyFizDjaOWPGM D0rYDfKRzj1-
pFz3NAHLXvgGxvtM0yxlv75Y9PtJLIOjIGmhdAjK3y+ijkYNEngOCWERP-
rGpF P7NbTWGY/mjbq33PvdPbjpXV8iPOaaSQo60AjgNS8Ha7deIku4Lu-
RPIgjhtrxJogw2g5aRGi PzbmP3MAjHStl/BUTmQnV9QDSaguokjyv9YA-
AF+593Cjj2610uW560vLkDmmBwuu+Cb+Szhs 7G5nubQ3s17LvljSRXfc-
cLmNlK7mc4YZ6YNdHbaLcy+E30fUbyV5popIXuUK7wrZxg7QMhSB nb+F-
bQOUqMEnjmkBg2fhGGz1DS7z+0LyWTTrRrNA/l4eMkZ3YUc/KvTH3frSw-
+DbCC9WYTXD QQ3LXltasV8u3mbdudeM/wATHBJALHjpjd575pctg/pTD-
Q5iw8D22nQWUMGq6gFsxcCPd5fW YlmY/J1yeKsjwfYHwMfCZnuGsjb/A-
GYSll80L25AxkfSt7kfnThgsCOmKQGNonhxNGury4Go Xl1Jd7DN9oKEF-
1ULvwqjBIC+3HSqUngi0li1Uf2jfrJf3i3olV0DW8ygBWjO30VRhs8D3N-
dI 2Q7Yz2oBbH86AMaXwrp9xYWVtfNNdyWl0l2lxO+ZGmX+I9umRjGMGr-
WkaJYaFZGz0+BYoTK8 u0DuzE4+g6D0AA7VfPPrSIOR9KAOWTwDZo0LDU-
r/ABFqb6qo/d485t2f4Pu/M3HvU8fgq1hj t3iv7xLy2nnnhu/3fmJ5zF-
pV+7tKsTnkccY6V0j5DDFICfU0hmAPB8EVzaXFrqF7byW0M0Q2 eW28ys-
HkdtyHLMwDenHTrUFp4HtLObTJYNSv1fTrFrCNtyfPESCob5f4Sq49cc5-
5rphu9ecU Nu3EjvxTEctZeA7PT7exgttU1FY7O0ks4sPGDsdgxOdn3gV-
XB/2R752tF0WDRo7pIpXlmupz cTyuqqXcqq5woCjhV6D361oRrlMH9Kc-
qBWzSuMXBxSjrg0UZANIZWUcDBI5qdeeM1CmamSgB +3rVTUNOg1TTbrT-
7pS1vcxPDKobGUYEHn6GrYoPHf86aEc7/AMIhZKE23V8GNuLWdvOybmIb
sK+R23NyuCNxANaF5pMN3aW9vHJJafZmDQPb4UxkAqMAgrjBIwQRWiaQd-
RTBHLWvgDRLCeCa zFzbmOLypUinZFuV3M37wD73zMx7feI6cVqy+HNJu-
NRvr+ayiee9thaXBYffi+bKn67sH12r 6Vg+JNHsx4h0GUiUtfaoVnzK2-
GUWsuFxnplFOPUZrF1y4k8I+Lkn06NriK08P3l00E924G1Z kc4JDc9QP-
50COlh8D2UWnGy/tHU3QPG0by3G9o1RgyIu4cKGVT0ydoyTRrPgTTdaur-
yae6vo /tiw+ckMoVWaJgyPyD8wwB6e2eabb+LL/UL4R6dpPnW8TwJcu1-
wqGPzESQkA9dqyKffnHSs/ XZtTh+Kdl/ZccU0zaJOfKuLho4ziaPnhW5-
7dO9AHUabo8WmXmoXUdxcSvfSiaRZWBAYKEGMD +6qj/gPrmqGnaB5uqa-
nq+q2FlFeX9utpKkDmQNGu7qxVTlgwB4/hXrisCz8a2k2pT6omnPG8 +k-
2dyjtcH5llkZURl+6uGJywzwfaoPHGu3r6HqumXUQt7yzlsJ1ltpmKyRy-
3AXrgEH5HBU+1 AG1/wr/TWs7aB7/VJJbSZJrW4kuN0kG3IVVyNuMMw5H-
Pc8DFm28GWdo+nmC/1BRp9xJcQIZF YBn3bgcr0wzD8fXmql344aCzvtU-
itBJpljfNZXDbz52VcRsyptwQGPTPI59iyPxrc3Wvrpdp YQvuuLiCTNw-
VeHyj951CnAYEFee6+vAGhryeGoJry4u3vbwSyRTRRMrqDbiUgv5bbcg5-
VTyT jHFbMKCKCOLez7FC7nOScevvXAeEvFr6no0FroGkor21lFcm2uLx-
vuyM4VFkIJY/Ics2Oo/D XHjAyeK7TQXtkK3ZmUSxzbthRA3JAxk5PGdw-
wCR81AHWCgmuN8P6hLpHw+ku44Z71raWfEas 0jsouHHuzYH1JxRY+Kr3-
Vr7RHs2sWs7z7QZTHKzcRgY6qNp55UgEHjtQFzsSecc0tec6l40f VbPV-
9HNsYZW0S5vUmgnLBSny7Q4ADH5lOVJHUdqJPE95Y+GDZ6ppcckL6BJeR-
tFetmZIkQSK x2Ao2HGCM/WgD0bIoFeda5ew6bfeJ5poZbqDy9NZ4PtTp-
hmkdcqw+6PunA4OPetVvEur2w8V XDWsE8WkT4jjSRlYxiCOQ/wnJw7H6-
8e9AHYUorFste+1WOo6iY0/s+2JMFxHJu+0IqBmZR6b tyjnnbWW3iy8V-
7OCazijbUrKW5snSYsMooYrJ8o28MMEZ6H2yAddnIpMYHWuCghi0z4Yvq-
8t s9zLd2FvcXkf2uRfMbYuWDfwsepxjJ6+taF54vvbTUr6BdNia2sbm2-
hklN0QzLNtAZV29Ru6 Ej60WA63jrSYwK4q78eXFtPrcP8AZ8ayaXaz3J-
imn2SSrHgqyjacqw3fMCdpGGwTVL4haxNP 4Z8SWGGha1sLa7jmimZS3m-
yOuCBjGPLPc5zQM9CyM0ZxXEah4nfRtS1R4dMWSc6lZ2jE3bYf zVVVbB-
XC4yOB19a2dC8QXGsQ6qj2scN1p109q6CYsjsqqwIbaDghx29aQG9n0pu-
K4VPiDeJZ 6VeXOlRpBq1m9xabLrcyusPmlZBtG0FQcMN30p0PjjWJ7TT-
Wi0GOa71OyN/bW8d51jCxkhmZ Rht0gGBkd80Ad1kY9KTPFcPeeOdSt59-
ZA0ePytHs4L26D3eH2OrsyqApBZQh/iwfWrreMjH4 htNKa2Upc3RtlkW-
TeV/dNIGbA2qTjG0nd3xigDqwaK5DTfF2o32l3eovYWkFvBcvagvenJdZ
vLYkbBx1I6k9MUxPFt9fQaFPaQRRpe6ncWc6TFgf3Sz9MrkZMOeQD2oA7-
AthsCkWTIOa5GHx MlvfLYW1ni8vNUuLZA85KFo03s5bGQCBwoHX86ji8-
XahcTW9omlxrdNqE2nyrJclVSRIzKGD BDuVlA7A89KdhXOy3rjNIJBjk-
44rix452w6NJd2q239oPJG0kkrGKN0k2FPMC4yfmI3bd2Md emjr2vX2l-
XqWtrZwzlrKe73SXBjGIjHleFbr5g/KiwHTbl20gZW461w1v47nmiV5LC-
FBc6ON Wtd92FBjJUbZGYAIfnX1HX8bUXjKd7C/uIrIO9rqVvp5V3aMN5-
vlYcbkz/y2HbtnvRYDrfNz xjikWToABXJWvjG4uWdJbGJJIdXOlz7Zyw-
DbQwdTtGRhhwQKxb7XbzxFNo1q8KQ20muXOnXU SzsfNWJJe4A4JXdj1A-
oA9KVgU3Ubl57Vw9r4wh0zULfRHtmaCO0uXWZZ2lO23wMMxGGYrz94 kH-
hqn1XXteg0gXUNnaRrI9r5Uv2guCJZVVlxt6gMOenPtRYLnYBx60F8Lkc-
1yOreLbvSV1Yy WUTtp5tuk5xIJW2/3eMfrRfeLb6yl1iT+zoXs9KmWGW-
Q3W1mZokdcArgcyKCSwxyeaLBc6/I xQZFwea5JPFWoC/t9JutLFtfXjS-
/Zg1wDG8aKGZyVyRgsFxjn+WbZXt/p3wq128jkC3ln/aT RsZDJsZJ5tv-
zMMtjAxn0osM7/evrR5gGK4PR573TJtKt7GxgkudVsRdzu97IqDyjEjEL-
tI3F ZQeMZI59au2fi6e/tdL1GG0jbT9SlaGCTzSHB+baWXb0O31JGR15-
wWFc68stIHUDrXB2fjjW L2ytphpVqPtdvcTRD7Y3ymFtrBv3fftjNa83-
iWVvCOma9a2qst81mBC8u0p57oo5APTzB+VF gOm3jn1pC2CM9646PxXq-
q3JjudOtUjh1JNPnaO7ZiGdVZGUFBkYkTOcfxenKr42aS10zVVtV fStQ-
vBZwush8wMzlEZlxjaSOecjP1ALAdjvUHGeaNy+tcNpfj2e8isLnULGK2-
tb1Loo8c5kZ TAzbsjaOCqk8Us/jttPis57yzC29/p8moWrxy7jtRVYq/-
AAOHXkEjr9aVh3O43r60gfkg8Yr l7rxDfWOo2umXVpbi71CbyrQpPuQg-
Izsz8ArjaR0+Y498VT4s1R76KwXTbdbo6g+ny77ohA4 g85WUhDlWXHoQ-
Tj3osI7JG3DNCtuYjHSuQ0rxncyvbnUbKK3hkgupGaGVpirW7hX+XaMg5-
JG OeOnNdHpOr2et2f2yxeRodxXLxNGcj2YA0NDL/alA5pvalByP/r4pD-
K6HipVNQJ6VOtCAkHe jBx0zQO9Y/irVJ9F8L6nqltHHLLa2zzKkhIDbR-
ntTQjYwfSgL7GuEuPGuo6ZdyWWpWdu1zM1 oLVoGbywJ5GjHmE/3SpPHU-
HinSeLtXt7y602SztJby0vrW2eUO0ccqT/AHWUYYqR0Kkn1707 COq1HR-
rbUp7Oe4E3mWcvnQGOVk2vtK546/KzDn1NVNV8KaZrF291eRStK9nJZMU-
mZQYXPzLg Hv69a51PGWtXFq9rbWNvLqqXd1bbUP7t/JI5AZl67l78cnn-
FRap461jTrG8vH0m2jWx0+C+n

Ri1CXzo7yKFoFlhlZG8tiCU47Ege/FZGj6nqdz8Q/EFjPcxmwtbWzaGEJyp-
fzCTnPXjn/gPp ytjdLrPjLXYLmMtDpcUVrHGzZVjJH5jvt6ZIZV56bTj7x-
oDQuv4P0WSa4la1b9/aJZsokYKI U5VVGflweQRSXPhDSr6yuLa8FxOLlom-
lledt7+W25BuzwAecD39TXA6BrN7pfha78IT3czam YFk0+4kyzSW8yltwP-
cxfvM54+VfXFM8O3E8/hT4faTKzx2GpmV7yZWZTK0alkiZh/fPOP4gh HrQ-
B6L/wi+lfa5pxE6iWdbmWESt5TzAgiQp03ZAPuRnrXO2PhbW01qWR5Hs4Gu-
5J3nt9UldZ FZy20QMu1cg4PPHUc1u33hjTXlupLYmznltTEDbvs2kEFZFX-
oGU98emc8Vl6nfS6z8F7rUrl V8260FrlsDo5h3ZH40AkW4fh9oFutmttBc-
wrbQ/Z1MV1IpeLcW2OQfmXJPWpYvAuiQail9DD cRTJcyXSbLh1VHkGHwuc-
AN1IrJPjO/0zUbrTNQsbfz1jtZLaSGZthWebyVDkrwQ3JI7dqk1H xXq+mW-
2qeZZ280ulyW8lw8YYK1vITl1HZkAYkZ6LnvT1A6C08O2djo50q3NwluXMg-
/fNvVi+ /huv3uagi8HaVAIAkUytHPLcFxMwMjy8yFsHnce3SsaXXbibxTo-
KNZWc0N5dXUdncB23oqRM d3p8xUjP93HrxUsPH2oNpS6vf2Vsto9vfSqkE-
rF91sxBBLADDAf5zwg6G1Z/D/QrB4WihuGW K1kslSS5kZfIc8x4J+7U7eD-
tLksJrOb7TLFJamyzJcMSkLYyinsDgZ7nAyeBTvD+q6rfTXUe qWCW8cYje-
CZXB81WzkbdxIxjr3zTfFWuXmijSks7aCeTUL5LMebIVCFlZt3AOfu0ANu/-
Bema h9sNy93J9sWFZv37Dd5R3J06YPPHXNSXeiSWb6lqGkwLPf3wQSwXM7-
LA5wqMxABwdijtztx3 rE0/xxd3t8mhtaww6x9quLZ3yzQfuURmdejHIkTj-
jvzxyyDxxqWo/wBjRWWnW6TXtzdW0wnn YCN4N27aQvzKSvWgDqND0K30Tw-
zZaGg823t7cQMWX/WcfMSPfk/jVaLwpp9vb+QhuWAt2tIm edmaGFsZRD2+-
6vPXgc8CskeJL/U9CfVbe0s59Jntrg+XLKySDZuwDwc7trZHVfeqGo+ONS05
LwW2mWhgsNIh1Jg0zKWRiwZF+Xg/IcUB0OqufD9pP4aTQX84WCxJBtWUhti-
9F3de1U7nwhYX bXrTSXZe8eF5ytww3NFjYeOmMDpVG38X399qzx2eleZYQ-
Xy2U8hlRWXIX5+W7FgNuMnqOwrV 1HVZ49cg0XTxB9tmtXui0+diorKvQdc-
lvwx9MsCFfBukmWd5IJJxMlxEVllZgqztumC+m48n 9MVWk8B6RPa3VrcPf-
TrdQR20zS3bszxxszKM59WNZ2l+ONR1/UtOs9O022iNxZzXEpuZm+Ro pxC-
6rtXkdSD9OlTeM/tA8ZeDvsfl/aDdXQQSMQp/0d+uKANK48G6fezTPcPds8-
08N0x88j95 H9xh6YwPyq9ZaLb6TJqU1kkrSXsrXEqs+d0hUDjPTgL+VYWj-
eMLzV7XSJRbQQm+W6jYEltkk LMpI9VJX61kx/ELVrrSdMvbbTbPfeaRcak-
wknYBfKIyvC993X/JQGr4e8Frb+FtOsNXSWS5t 7P7KN029Ysptcxntu/MA-
44FaE/g3S5bDSrYLcIdLj8u0linZJI48BSm5TkggAfgKy7fxnfNc 3cM9la-
If7Lh1KA/aDjbIxXa5IHORnj6Utt4yvLixvmSyia4tNYj0xi7NErhmjG/aQ-
Sv+sHyn /CgBIfBzv4r1i5ulZdKvLa2t0hSXiRYwwZZF/uncPyPrzpP4K0o-
Xz3yC6WVrwXuEuXVVm2b CwAPdeDVrw1q1zq9tei9hiiubO7ktn8piyNtxh-
hnkcEVhWviG9+zadDZabaRSX2q3to4M7bU eNp2Lfd53GInt96n1A1F8H6a-
mlvp6faViN39tV/PbekxbcWVu3zZP4mlHhDTUtEtkN2oivHv Y3F1JvSRi2-
7DZyN3mPn/AHjWLF45mfR9O1B4YbWG4STz5pgzQpIknl7TIOIwSGIZuOMVL-
H4v vTI4e2twseuf2U+Gb5lKghx6HnpSA1pPCumypkiUSrdteRzCQh45WGG-
ZT2yO3SnJ4W0+OS0k iE8b2s0lyhWVvmlcMHdv7xIY9fXiuZ0e+Frf6FZCy-
gm+0atq8cUzscw7JZzhR0wQoHsKfpPj 3UrxLZ5tKgP2y0vZreOCYli9vJt-
2ncAPmyOaYG4ngzSxYLYN9oe05DxPOzLIpcvtfPUbiT+J 7Ve1DQ7XVLoXM-
zTCQQSW37uQqPLfbvGPfavPtUPhfW21uxu3kaHzIJRGY1Ro3T5VOJI2+ZGy
Tx3AB71zVh4u+xaBZTx2FvY2811eK7ks0MbpOVwzfw7zuO4/KMY7igDZm+H-
2iTW0VuyXJSKx /s+Mee2Ug3KwUfRlU56/LU//AAiOnn7Qpe7P2i4huZCbl-
yWki27G5Pby0/75FXtc1O4062s2 toIppLi6jt8SSFAu44zkA1zth41ub37-
LYG0gj1O51G608NuJhUwBiz+pyF+779aQWNNvCGm+ TeIouEN1eC+kdZ2DC-
YYG5T/DwoFNtfBmk2sls8KXANveyX0ZNw7fvnzuY5PPDMPxNZ9t4i1P UtU-
0WONIbWNr66s72Ioz72iV+Y24+U7c9PT0IOp4j1280y8tbDTrL7Xe3EE1wi-
FgBiPYCvJH J3jnt1oAr23gXRbee2lSG4ItRMIYzcOURZT86bc42n0qWHwX-
pkWmS6bm8eFwqqZLqR3hVWDK IyT8uCq4x6D0rPg8Y3kmqiCaxW2Dwh4YZG-
ybj9x5h8uUfISGypX0BbpUUPjO8uooYLaGGW/m lkjVCjRGPYiMVaNyG3/P-
0z0+b2pga2o+CtL1VpGuluz50UUcoW5dRII23IWweWHrVhvDWmSW 2qRTwv-
NDqePtUcsjMJMIqZ9vlVRx6etc/eeMNbtrW/m/sq1hex0qLUriGW4LEZMm+-
MbRjP7o 4Oah1TXb9b3xwt0lvd6Zp2lwyx2bZTdujkZwWGeuD+lIDa/4QvS-
/s9ujG8M9s++C8a5czx8Y wJCc7cHG3pVlPDunJoN7owExtL3zTOjTuzN5j-
Ev8xORncenrWJc+MZdPl0tBawm1uJrW1aOP cWQzDg7ui7cj5TyR6VzaceJ-
8qx/5HdkyD/CbTJH0yAaYHotvoVpbXdncp5xeyt2toC8pIWNi uRjv9xef9-
kVHZ+GLC0mDwJKiLLJLHEsreXDI4bcyL2J3N+Zx1qloPiC91LUZdOu4IILy-
1uJk uYgSf3a7djrz/FuU/n3FZvxA1WefQPEmlWggU2ukm6neXOSGEgATHc-
eWTk+3rwrgbEPgzSLW O2hhW5WO3jliiX7Q52rKcv35z7/hVgeHrD+w7TRs-
SiztXiaBRK2R5bBk56naVX8hXGXupSJp 2rW9tbQQ3UWi2Lfa+S8iuXXa3T-
GMNjHrRqcFt4b1zWLyeztZ7SzsLfUBbx7kxOZH+ZWLYQFo 1z2wPrl9AOwP-
hTTZWkkYXJZ7tb1v9IbmZQArdenyrx046VJB4dsLa482KOUKJmuEhMrGOOVs
7nVexO5vbJPrWDJ4o1+3tpEm0q2Wb7VaxRPJMFEiTNt3bFLEbTkcnnqPSkt-
vFetXGqPaRaXD MlneR2V8yShQHZFYupZgdoL4C7SW9aQGzZeDdKsRYeTFc-
BbBpTbqZ3YKZSd+cn5s7j1pYfCm kRW5t3tfOhFs9rHHM5ZYoWwGjUHopwP-
yHoKw9A8Yavqf9mG5tbOKPUku1h8pmYxyQuw+bOMq QP8AOeN/wxdX174Ss-
ry+mhku57dZS6R7VyVz0zQhleHwfo8dpFAsU8jwSLJFcSXDvNEyZCbZ CSc-
AMwA6fMfU5sf8I1YGa1m2T+dbTNcK/nNkyMpVmbn5jtJHPQcCuG8Palfwab-
4avba2sZtY 8QedFNdSF0HyiWRSyrnPIPPpx9N+88Z3NrBdX628EtlY38en-
3Ua7hIZGKKXQnsGkHykcgZzQ I29N8LadYS2k1stwHtGm8otO7Y81tz5yec-
kA85rbVWDN2WvPovG2tNqxtRY2KwtrMmkp+9fc rCLzFc8cj72R7j8eo8Ka-
1NruiC7uYo4rhJ5reVYySpaORoyVzzg7c/jSGbYx2xilHBpKOCeu aQysg6-
VOoxVYD5R35H86sJQhslA5NZHijSptc8MalpUDpHJeW7wB5M4XcMZ4+ta4r-
nPHs1xb +A9cmtZ5IJo7KVkkjOGUhT0Pb600SSwaDpUmnvptzDbzSmKL7RG-
ZDIRt+51+YAEEr0wenNSv 4Z0p1CtaEnz1uS/mNvaVQArs2ckgAAZ9BXFat-
fXtlqOv6ppmqx/6DoEFwWMSv5zI9yQpPQDh gcDPI5GObGreMr2y8X2dpDf-
27Wj6jDazJsAEKtAzsGY8lsgNlflAwDyaoR1Evg7Q5o2SSy+9 cNdZErhhK-
2QzBt2RnJzjrTrjwjolzBLDJp6+TLbpavErsqGFfuptBxgc/mfWsrwTeXFw-
mvtd X0l1LHq91GqPtyqI21cAD0AFUdK8R6rqUXh7UPtISLV5Jop7LYpa2w-
jsCrYzlCgVtwOS3bpS DQ6O2tPD41mfUIXtn1CKNUnkE+5lVQygsM9QCwye-
eW96lTSom1WTU7WSPyr2BUuAn/LQKDsd WXvhsZ7jbyNvPPeHh9m+FkGoRP-
G94NMLLPLGrEYTdg9MjPb3rEfxJ4glsYJYNUt4P+KXXVSg tl5lAHv900Ae-
hDQtOESJ9l/1du1sjFmLLE2Nyhs5x8q/lVf/AIRnRYNBTSWs4102AiRInc4i
K8hlJOVx1yOlc3f+JtSi8TpZtK9tazvst5o41kjdjbl/Kb+JJN3zjPylRis-
yx8XXur2thb3N 3BIl/wCGJ7y4RVX/AFwCj8PvNx7UAdnNptvNbXFnpt4I7-
u5gCvceeZZo4mzhlLEnrnb2zzz3 0E0mzTRV0cwKbEQfZvII+Ux7du36Yrz-
mfxFqmmWeqrZz2yGy8LW99AzQBir/ADDaT3Hy8f71 dJ4V1bVLu+1ay1G8i-
uWtxbSI8cQTaJI9xXGfXOPYigDZPhjSZLS6tZbFJYrpFjn85mdpFX7o LMS-
cDnHPFWY9Isora4txCWS4GJvMdnMg27eWJz0GK4Vdd8S29/DcvqVpcW/9tH-
Tns/s2xmjL 7dyncTuUfMe20H0qCz8U66dOS6vNTtNl1q0unK5iESwCN5cN-
uORltiKMjqw9aYHd/wDCO6YH 01ltAp0xNlnsZl8ldu3Awf7vFQweE9Gt4Y-
YY7IeVCJVSNpGZQJc+ZwTg7snOa5cX/ii6v9M0 xNd06KSezu5JLiK284Fo-
pY1UjLKM4kG7jGVb1GMS4+IusjSbO8aS3juVS1FxbLF3e4MZkYt/ A6jcgX-
nnJ4oA72LwbpNpYxWllA9vHFPDKuJXYjym3KoJbhevy9OTxUfizw/c66dGF-
vJGiWOo x3sm+RkLKqsu1So4PzZz7e9c9c+JNZ/tPxPOutWFrp+kBGiMtqW-
Rg8G4FmU5wGZT8o5xjvVa 48T6lfab4ksWuJraSxktvLlbyxKY5Au7IXI9f-
fDc80gO3bRNJnEdr5S+ZayG4UpKwkjdt2W3 A7stlvrzTk8N6XHLYSR2YRr-
AsbbYxURlhhjgHBJyck9c1ymreKbzRr7XtkkF0sMNiIZPLC+V 5sjxs0jD7-
wXG7t6cdabqHiDXbO71bT4bmNzZ3dgkN5LBu3JcSKjIwBA3LnOR2YcDqQDp-
Y/CG iRz3k8djse8LmbbKwVi/32C5wpbuRgnNLN4R0a4FwJrPcLi1Wzl/ev-
8ANCvROvTr+Z9a5MeL NbhstUR9902n6xJZvJaxIJTCIQ+/YThiCwyF52g8-
Vt+ItY1O30/QX068t0e+u7eCSV4SwZXU 8qMjHrQBpxeE9Gt9T/tGOyC3Xy-
lm8xsMyjarMudrMB0YjPvVy90i0v7mC5nibz7fcIpUkZHQ NjIypHBwOOnA-
rjtN1zXRqGlNeahbzQT6teaa6Lb7SyxCfa5OfvfuhkdOap6T401PUdRvrWK+
tHT+yPttvcCLMZk811yoyCUwo64PBPSgDt4fD+nW19b30FqI7i2tzbRMrEb-
YyclcdOoH5Ut9 plld3dpfXkeZrEtJDKXK+WxG1jx7ZHPauIi8Ta+mhapPP-
ewS3MehRarA0dvtCOyykrgk7l+R f16ZGK/jzWprrQvFVil6rwRaXaXC7Au-
VaSSQMM+mEX8/egDrbLw34fudPt4bONHtbeWR4jDc MQrNneNwbodxyvSpI-
/BWhQQQ28ViVihtXtI0Ez/LC/3l+90P9BXL694outB8Qx2llNbPG99Z Qzx-
rAFK+czK7yNwNzADbt6bTnitK11y91driSLWILZo7u5tZLMIpdFTeq4zk7y-
VWTnjaeneg DYk8H6JLkPZkk2q2mfOfPlKcqv3ux5HeiHwho8An2W0g+0XC-
XUp8+QlpVxtc/N1+UH8BXJ6d r+oWul+CkbUi6alZt9okmCEqy23mBg3rn1-
qPRvE/iHWJfCqx31pGNQ0tr25/0bcWZJEDKPm4 yGI9vegDv9P0m10wXP2S-
N4/tErTS5kZtznqfmNUoNB0ZZYkgT95aTvcqq3DFo5JN25vvdW3N /wB9H1-
rj7PxjrD6OutSXmnNaXFsG8kNl7aVpEUkgD7iBzvBOQV961vDCNB4x8SiS5-
S4eQWr7 wqq2Njfe28E+/pigLo0h4b8OrF/ZKQQlVRh9kM7HcpbcwZc/Mu7-
nnPWpJvB2iSXUl21hmZpx dn944HnAYDhc4DYA5ritOur+10DWNTt7mGS9j-
8UPbxyXcIk2K9ysJ2kEEfKw79FxxWtd6zra DV7L+0Y47zSbNJ/Me1CrdFg-
zbtufufLt4P3t3pQB0sfhfS4p7edLZhLbSyzRN5r/ACPLu8xu vVtzZ+tQw-
+DtEt0hSOy2iGOaKMea/wAqynMgHP8AEeTXEz+MfErjVb+OWC2hs4NPuFsp-
bb5x 5+N8btngjnnHX9e08P3eoSS6xZX13HcTWdyI45lh2ZVokcZXPYsfwx-
RqF0adjpNrp5uGtoSs lwweZ2ZmaRgoUFmbJOAAKpR+FdIjtFtUtGWBfM/d-
+c+G8xtzgjPzBiMkGuQi8TeIYdP0+e81 Gyb+0tQlsFcQeSkPltN824s3L+-
WoAI4z3p9v4m1y5nn0u41PSrS/tLRbj7Sn7yG4PmspHOOF VMNj+J/bBLAd-
5eabb36RLcRlhDKs0eGZcOOh4qgnhTSFQqLMf8fTXasJG3LM2dzq2cqTk9PW
uYS/8XarJ4o/s7UbRW026lt7WA2ufNPlo6AsW4+8R+Pam3Hi3UptJi1bTX8-
2zmkij8pEUzAC JmlMYON7q2AU6jy379CwHYnQdOKWiG2/49JTLDhjlXO7c-
c5y2dzZz1zzUetaJpOqi2fVYUYw PmGQyGMox+XhgQec4x3rjE8R3kf9o6k-
2uW+1dCsrqKSWPFvvcz5faBv2naDjr2pbjW7jVdN1 a3vFP+g6zZxw+aqB9-
haBsnacZyzfgQDzmiwXOp/sbw/50j7LcZlCMgmwgkMfl4252hvLIXpn FPu-
fCOj3iKtxZtIyzCdZWmfzFk27dwkzuHygDrXBW+pz6ZPq72wg/f8AjG3gkE-
kW75XSEHb6 H3q/d+K9UtW1K8i1O2k060TyFubiNVjlui2G245KRDcW55xj-
PytQB103hbSplmSS0PlzWq2c iiV1DQrnahAPT5m/M+tQSeF9E1H7VcG2Wb-
7XELeZxOzCRFDLg88kZZc9eSKwbfxHqo1Sz0a9 vLMi9uJvLvbVg5WNY1ZU-
bI2+Y27PT7oPHek0a9u9K+Fmp3dtPC11ZtqUquYvkZkuJmztB4Bx 0oA37j-
wXolyytLYbirxOP3rgbowAjY3feAAGetTL4T0kXZuvsX777X9t3eY3+v27d-
+M9ccfS uIk8a+INEiMl6YL+K50yO9jligKLbM0iR/Nydy4fdnj7jfho+Id-
f1/R7fW47a9t52tre3
 
willbill wrote:
> Sabine Hancl wrote:
>
>> It is the first time I hear, that it is possible to
>> exceed the used-by date of the insulin for years.
>
>
> synthetic "human" insulin lasts close to 100 years with
> good refridgeration and 5% potency loss (same is true for
> pork and beef):

Keep in mind, no one has actually *tried* this stunt. It's
extrapolated from much shorter tests.

It's really important to remember when you buy stuff that is
rated for "10,000 uses" or "7-year expected usable life".
Manufacturers have been known to make a small change without
actually testing things properly, then had all of the units
start failing after a much shorter period. This can occur
with medications, as well as with CD's, hard drives, and
paint jobs.
 
> when it comes to insulin longevity, i'll trust Brange and
> my own experience (and mickey too, for that matter) and a
> few others (like nas) long before i'll trust a numnut
> like you
>
>
For me it is not of particular relevance to know, that
insulin is durable for 100 years. It is important for people
with an intolerance of GE insulin to know, that animal
insulin is continuous available for the rest of our life.
...Sorry, it is necessary to know: What about the next
generations with diabetes...? Sabine

http://gopetition.com/region/79/3152.html
 
Nico Kadel-Garcia wrote:

> willbill wrote:

>> Sabine Hancl wrote:

>>> It is the first time I hear, that it is possible to
>>> exceed the used-by date of the insulin for years.

>> synthetic "human" insulin lasts close to 100 years with
>> good refridgeration and 5% potency loss (same is true for
>> pork and beef):

> Keep in mind, no one has actually *tried* this stunt.

it's not a stunt stupid, it's real

both Brange and my own experience (3 occasions, out to 4+
years beyond the expire date) say to me that 100 years with
half decent refridgeration is real (provided that the
insulin is non-acid)

alan mackenzie was supposedly going to give a try to some
long expired R ("human"?) that he recently found where he
lives (at room temp?)

i'd welcome his *detailed* inpu about that (assuming that he
had the balls to give it a try)

> It's extrapolated from much shorter tests.

when it comes to insulin longevity, i'll trust Brange and my
own experience and a few others (like nas) long before i'll
trust a numnut like you

>
> It's really important to remember when you buy stuff that
> is rated for "10,000 uses" or "7-year expected usable
> life". Manufacturers have been known to make a small
> change without actually testing things properly, then had
> all of the units start failing after a much shorter
> period. This can occur with medications, as well as with
> CD's, hard drives, and paint job

when it comes to insulin longevity, i'll trust Brange and my
own experience and a few others (like nas) long before i'll
trust a numnut like you

bill t1 since '57, ex 8-yr pumper, pork/beef-L 2x,
simple MDI/DAFNE
 
Nico Kadel-Garcia wrote:

> willbill wrote:

>> Sabine Hancl wrote:

>>> It is the first time I hear, that it is possible to
>>> exceed the used-by date of the insulin for years.

>> synthetic "human" insulin lasts close to 100 years with
>> good refridgeration and 5% potency loss (same is true for
>> pork and beef):

> Keep in mind, no one has actually *tried* this stunt.

it's not a stunt stupid, it's real

both Brange and my own experience (3 occasions, out to 4+
years beyond the expire date) say to me that 100 years with
half decent refridgeration is real (provided that the
insulin is non-acid)

alan mackenzie was supposedly going to give a try to some
long expired R ("human"?) that he recently found where he
lives (at room temp?)

i'd welcome his *detailed* inpu about that (assuming that he
had the balls to give it a try)

> It's extrapolated from much shorter tests.

when it comes to insulin longevity, i'll trust Brange and my
own experience and a few others (like nas) long before i'll
trust a numnut like you

>
> It's really important to remember when you buy stuff that
> is rated for "10,000 uses" or "7-year expected usable
> life". Manufacturers have been known to make a small
> change without actually testing things properly, then had
> all of the units start failing after a much shorter
> period. This can occur with medications, as well as with
> CD's, hard drives, and paint job

when it comes to insulin longevity, i'll trust Brange and my
own experience (and mickey too, for that matter) and a few
others (like nas) long before i'll trust a numnut like you

bill t1 since '57, ex 8-yr pumper, pork/beef-L 2x,
simple MDI/DAFNE
 
willbill <[email protected]> wrote on Tue, 22 Jun 2004 16:54:43 -0500:
> Nico Kadel-Garcia wrote:

>> willbill wrote:

>>> Sabine Hancl wrote:

>>>> It is the first time I hear, that it is possible to
>>>> exceed the used-by date of the insulin for years.

>>> synthetic "human" insulin lasts close to 100 years with
>>> good refridgeration and 5% potency loss (same is true
>>> for pork and beef):

>> Keep in mind, no one has actually *tried* this stunt.

> it's not a stunt stupid, it's real

> both Brange and my own experience (3 occasions, out to 4+
> years beyond the expire date) say to me that 100 years
> with half decent refridgeration is real (provided that the
> insulin is non-acid)

I'd have to side with Nico on this one. Nobody (so far as
we know) has tested insulin many years after it's expiry
date. Several years is as far as we've got. We don't know
for sure what the stuff's going to be like after 30 years
in the fridge. But I'd agree with you, it seems a
reasonably safe bet. (For me, personally, 30 yo insulin is
likely to be safer than whatever analog is going to be
fashionable in 2034.)

> alan mackenzie was supposedly going to give a try to some
> long expired R ("human"?) that he recently found where he
> lives (at room temp?)

Haven't yet done so.

> i'd welcome his *detailed* inpu about that (assuming that
> he had the balls to give it a try)

I'm not short of gonads. Just that around the time I posted
(12th April) I was having trouble with morning BS values, so
my Doc suggested Semilente before breakfast instead of at
lunchtime. That didn't work too well, so now I'm trying it
both morning and lunchtime. It's still not working well. It
may well be that I'll go to using Lente (Novo's Monotard MC)
instead of (or as well as) Semilente. And there lies an
irony: Lente (made by Welcome) was the first insulin I was
stabilised on in 1965. Talk about progress!

I fully intend to test this 7½ year old Actrapid just as
soon as my general control has become stable enough to make
it worth while trying.

>> It's extrapolated from much shorter tests.

> when it comes to insulin longevity, i'll trust Brange and
> my own experience and a few others (like nas) long before
> i'll trust a numnut like you

Hey, steady on Bill! Nico isn't suggesting the results in
Brange are rubbish. He's just saying that beyond a timescale
of several years they're untested. They're a reasonable best
guess. He believes them as much as I do, but it doesn't do
any harm to treat them with a little reserve - the
scientists upon whose data these results are based would
certainly agree with this.

> bill t1 since '57, ex 8-yr pumper, pork/beef-L 2x, simple
> MDI/DAFNE

--
Alan Mackenzie (Munich, Germany) Email: [email protected]; to
decode, wherever there is a repeated letter (like "aa"),
remove half of them (leaving, say, "a").
 
Alan Mackenzie wrote:

> willbill wrote

>> Nico Kadel-Garcia wrote:

>>> willbill wrote:

>>>> synthetic "human" insulin lasts close to 100 years with
>>>> good refridgeration and 5% potency loss (same is true
>>>> for pork and beef):

>>> Keep in mind, no one has actually *tried* this stunt.

>> it's not a stunt stupid, it's real
>>
>> both Brange and my own experience (3 occasions, out to 4+
>> years beyond the expire date) say to me that 100 years
>> with half decent refridgeration is real (provided that
>> the insulin is non-acid)

> I'd have to side with Nico on this one. Nobody (so far
> as we know) has tested insulin many years after it's
> expiry date.

bill van antwerp (MiniMed) (who's posted here (m.h.d.) in
the past, but is now absent for "a while" (likely due to his
new boss (Medtronic)) has to some extent (out to 20 real
years?), but BVA's not a full- time insulin person (like
Brange), and my guess is that Brange has real 20+ year
experience

> Several years is as far as we've got. We don't know for
> sure what the stuff's going to be like after 30 years in
> the fridge.

formulation is everything! and my hunch is that acid based
insulins are very short lived

> But I'd agree with you, it seems a reasonably safe bet.
> (For me, personally, 30 yo insulin is likely to be safer
> than whatever analog is going to be fashionable in 2034.)\

:)

>> alan mackenzie was supposedly going to give a try to some
>> long expired R ("human"?) that he recently found where he
>> lives (at room temp?)

> Haven't yet done so.

:(

>
>> i'd welcome his *detailed* inpu about that (assuming that
>> he had the balls to give it a try)

>
> I'm not short of gonads.

i never doubted that. :)

> Just that around the time I posted (12th April) I was
> having trouble with morning BS values, so my Doc suggested
> Semilente before breakfast instead of at lunchtime. That
> didn't work too well, so now I'm trying it both morning
> and lunchtime. It's still not working well. It may well be
> that I'll go to using Lente (Novo's Monotard MC) instead
> of (or as well as) Semilente.

if you can still get Novo's pork-Lente (a.k.a. Lente
Monotard MC), i suggest that you immediately stock up 15
years worth of it coz it is probable that it will soon
disappear (as it has in USA/Canada)

(the recently discontinued Lilly-pork-Lente was likely
Novo's (offered/re-labeled thru Lilly per our not so lovely
FDA/USDA))

> And there lies an irony: Lente (made by Welcome) was the
> first insulin I was stabilised on in 1965. Talk about
> progress!

real insulin progress stopped in 1982, with the arrival of
Lilly's rDNA synthetic "human"-insulin

>
> I fully intend to test this 7½ year old Actrapid just as
> soon as my general control has become stable enough to
> make it worth while trying.
>
>
>>> It's extrapolated from much shorter tests.
>
>
>> when it comes to insulin longevity, i'll trust Brange and
>> my own experience and a few others (like nas) long before
>> i'll trust a numnut like you

>
> Hey, steady on Bill! Nico isn't suggesting the results in
> Brange are rubbish. He's just saying that beyond a
> timescale of several years they're untested. They're a
> reasonable best guess.

incorrect

Brange's insulin longevity table (in "Galenics") is bettter
than a "reasonable" best guess

> He believes them as much as I do, but it doesn't do any
> harm to treat them with a little reserve - the scientists
> upon whose data these results are based would certainly
> agree with this.

:(

see immediately above

bill t1 since '57, ex 8-yr pumper, pork/beef-L 2x,
simple MDI/DAFNE
 
willbill <[email protected]> wrote in message news:<[email protected]>...
>>
> anyone on a.s.thyroid have a clue as to what percent
> marketshare Armour Thyroid has in the USA?
>
> i'd think that it's more than 1%, but wouldn't bet any
> large amount one way or the other
>
> if you have a clue, kindly also cross-post it to
> m.h.diabetes. thanks

The Armour market share is tiny, but probably more than 1%.

The drug companies keep their numbers close to their vests,
but Synthroid in 2003 is now the #2 most prescribed drug in
the USA, based on pill volume. It was #3 in 2001, but rose
after Premarin's sales dropped off.

Since its cost is lower than most meds, it is much further
down the list if you rank by sales dollar volume.

Armour doesn't show up on the radar screens that are
publically accessible.

FYI, here is one source of free reports.

http://www.pharmalive.com/specialreports/sample.cfm?report-
id=4 http://www.pharmalive.com/specialreports/sample.cfm?r-
eportid=12

These surveys validity are somewhat similar to movie
sales figures in that you are relying on the accuracy of
the companies reports. Some pharmacies, notably Wal-Mart,
do not report sales figures to anyone other than their
own headquarters. Thus the accuracy of these ranking may
be suspect.

If I had to make an educated guess about Armour's market
share , I would say 3 or 4% based on pill volume.

Levothroid has dropped due to their "reformulation" (i.e.
bought another drug and relabeled it), and Levoxyl and
Synthoid gained.

I suspect Synthroid will drop somewhat this year, because of
the recent FDA ruling making generics available. Since the
bioequivalence of all the levothyroxines from one brand to
another is poor, we don't recommend switching to a generic,
or to a different brand, from the brand currently used. If
you do switch, you need to get rechecked to verify the
dosage is still correct.

For a background on this, check:
http://www.aace.com/clin/guidelines/levothyroxine.php

Cheers, William C Biggs, MD
 
In article <vPoEc.25892$Lh.6868@okepread01>,
William C Biggs MD <[email protected]> wrote:
>Bill,

>> out of honest curiosity (and i'm NOT trying to start any
>> fights!), do you ever prescribe Armour to your own
>> patients? if not, why not?

>I used to, but not any more.

>Armour is WAY too variable in potency from one batch to
>another. It is a living nightmare to keep the levels steady
>with Armour. I can't imagine treating hundreds of patients
>with thyroid levels creeping all over the map.

Aren't there FDA regulations on variability in potency?

--
This address is for information only. I do not claim that
these views are those of the Statistics Department or of
Purdue University. Herman Rubin, Department of Statistics,
Purdue University [email protected] Phone: (765)494-
6054 FAX: (765)494-0558
 
That sounds about right. Armour isn't anywhere near the top
of the charts as far as sales, now, how do we fix that?

"William C Biggs MD" <[email protected]> wrote in
message
news:[email protected]...
> willbill <[email protected]> wrote in message
news:<[email protected]>...
> >>
> > anyone on a.s.thyroid have a clue as to what percent
> > marketshare Armour Thyroid has in the USA?
> >
> > i'd think that it's more than 1%, but wouldn't bet any
> > large amount one way or the other
> >
> > if you have a clue, kindly also cross-post it to
> > m.h.diabetes. thanks
>
> The Armour market share is tiny, but probably more
> than 1%.
>
> The drug companies keep their numbers close to their
> vests, but Synthroid in 2003 is now the #2 most prescribed
> drug in the USA, based on pill volume. It was #3 in 2001,
> but rose after Premarin's sales dropped off.
>
> Since its cost is lower than most meds, it is much further
> down the list if you rank by sales dollar volume.
>
> Armour doesn't show up on the radar screens that are
> publically accessible.
>
> FYI, here is one source of free reports.
>
> http://www.pharmalive.com/specialreports/sample.cfm?repor-
> tid=4 http://www.pharmalive.com/specialreports/sample.cfm-
> ?reportid=12
>
> These surveys validity are somewhat similar to movie sales
> figures in that you are relying on the accuracy of the
> companies reports. Some pharmacies, notably Wal-Mart, do
> not report sales figures to anyone other than their own
> headquarters. Thus the accuracy of these ranking may be
> suspect.
>
> If I had to make an educated guess about Armour's market
> share , I would say 3 or 4% based on pill volume.
>
> Levothroid has dropped due to their "reformulation" (i.e.
> bought another drug and relabeled it), and Levoxyl and
> Synthoid gained.
>
> I suspect Synthroid will drop somewhat this year, because
> of the recent FDA ruling making generics available. Since
> the bioequivalence of all the levothyroxines from one
> brand to another is poor, we don't recommend switching to
> a generic, or to a different brand, from the brand
> currently used. If you do switch, you need to get
> rechecked to verify the dosage is still correct.
>
> For a background on this, check:
> http://www.aace.com/clin/guidelines/levothyroxine.php
>
> Cheers, William C Biggs, MD
 
William C Biggs MD wrote:

> willbill wrote...

>> anyone on a.s.thyroid have a clue as to what percent
>> marketshare Armour Thyroid has in the USA?
>>
>> i'd think that it's more than 1%, but wouldn't bet any
>> large amount one way or the other
>>
>> if you have a clue, kindly also cross-post it to
>> m.h.diabetes. thanks

> The Armour market share is tiny, but probably more
> than 1%.
>
> The drug companies keep their numbers close to their
> vests, but Synthroid in 2003 is now the #2 most prescribed
> drug in the USA, based on pill volume. It was #3 in 2001,
> but rose after Premarin's sales dropped off.
>
> Since its cost is lower than most meds, it is much further
> down the list if you rank by sales dollar volume.
>
> Armour doesn't show up on the radar screens that are
> publically accessible.
>
> FYI, here is one source of free reports.
>
> http://www.pharmalive.com/specialreports/sample.cfm?repor-
> tid=4 http://www.pharmalive.com/specialreports/sample.cfm-
> ?reportid=12
>
> These surveys validity are somewhat similar to movie sales
> figures in that you are relying on the accuracy of the
> companies reports. Some pharmacies, notably Wal-Mart, do
> not report sales figures to anyone other than their own
> headquarters. Thus the accuracy of these ranking may be
> suspect.
>
> If I had to make an educated guess about Armour's market
> share , I would say 3 or 4% based on pill volume.

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

thank you for your educated guess, i appreciate that. :)

out of honest curiosity (and i'm NOT trying to start any
fights!), do you ever prescribe Armour to your own patients?
if not, why not?

after all, Armour is the cheapest source of T3 in the USA
(vs. either Cytomel (which is pure synthetic
T3), and/or Thyrolar (which is a synthetic T4:T3 combo)

also, do you have any insight into what happened to the
recent shortage (stoppage?) of Thyrolar, and if you do,
would you kindly share it with us. thank you in advance

>
> Levothroid has dropped due to their "reformulation" (i.e.
> bought another drug and relabeled it), and Levoxyl and
> Synthoid gained.

given my long posting (on misc.health.diabetes) on pork and
beef insulin being superior to all of the new synthetic
insulins (for at least some subset of the small type-1
diabetic community, which i know has rubbed you the wrong
way), i'm sure it didn't come as any surprise to you that i
started with only Armour for my 1st 5 months of using
thyroid medication

i bet that what did surprise you was my moving to a combo of
Synthroid and Armour. <grin>

...with my than half of my current intake being... ta da:
Synthroid! (i do listen to my doc, and his early comment was
that my T4F and T3F numbers were out of balance, suggesting
taking more T4)

he gave me a ton of Synthroid samples :) , and a script for
100 tabs of the small Levoxyl size (25 mcg), since i
figured that when i started using synthetic T4 i'd go with
whichever of the name brands was cheapest, and Levoxyl was
certainly cheaper than Synthroid (at least at a local Wal-
Mart, but i didn't do any serious shopping around beyond
that at that time)

anyhow, i used the small Levoxyl tabs for small dose
adjustments. i told my doc that that was what i planned to
do, and that if i could be trusted to use insulin on my own,
then why shouldn't i be allowed to make minor dose
adjustments of my thyroid med amounts? (which my doc didn't
seem to get upset about, thank goodness)

i'm still getting my Synthroid mail-order from Canada, but
if that comes to a halt, i'm planning to give Levothroid a
try coz i can buy it mail order in the USA for about the
same as what i'm presently paying for Synthroid from Canada.
the unknown about Levothroid is whether or not it will split
OK 4 ways. (Levoxyl crumbles when split 4 ways, but what a
great pill shape for splitting 2 ways)

>
> I suspect Synthroid will drop somewhat this year, because
> of the recent FDA ruling making generics available. Since
> the bioequivalence of all the levothyroxines from one
> brand to another is poor, we don't recommend switching to
> a generic, or to a different brand,

thank you for that comment, coz we have a new dude named
ronnie posting in alt.support.thyroid and having a real endo
say this will have more meaning (assuming he reads this
thread; i changed the title but depending on his n/g reader
he may or may not see it)

> from the brand currently used. If you do switch, you need
> to get rechecked to verify the dosage is still correct.
>
> For a background on this, check:
> http://www.aace.com/clin/guidelines/levothyroxine.php

again, thank you for your percentage estimate for Armour
thyroid, as well as the above 3 refs

bill type-1 diabetic since '57

>
> Cheers, William C Biggs, MD
 
Herman,

Not for Armour thyroid.

It is dispensed by dessicated weight, not potency.

Cheers,

William C Biggs, MD

"Herman Rubin" <[email protected]> wrote in
message news:[email protected]...
> In article <vPoEc.25892$Lh.6868@okepread01>, William C
> Biggs MD <[email protected]> wrote:
> >Bill,
>
> >> out of honest curiosity (and i'm NOT trying to start
> >> any fights!), do you ever prescribe Armour to your own
> >> patients? if not, why not?
>
> >I used to, but not any more.
>
> >Armour is WAY too variable in potency from one batch to
> >another. It is a living nightmare to keep the levels
> >steady with Armour. I can't imagine treating hundreds of
> >patients with thyroid levels creeping all over the
map.
>
> Aren't there FDA regulations on variability in potency?
>
> --
> This address is for information only. I do not claim that
> these views are those of the Statistics Department or of
> Purdue University. Herman Rubin, Department of Statistics,
> Purdue University [email protected] Phone: (765)494-
> 6054 FAX: (765)494-0558
 
Bill,
>
> out of honest curiosity (and i'm NOT trying to start any
> fights!), do you ever prescribe Armour to your own
> patients? if not, why not?

I used to, but not any more.

Armour is WAY too variable in potency from one batch to
another. It is a living nightmare to keep the levels steady
with Armour. I can't imagine treating hundreds of patients
with thyroid levels creeping all over the map.

> after all, Armour is the cheapest source of T3

Not after you include the costs of extra doctor visits and
lab testing.

> in the USA (vs. either Cytomel (which is pure synthetic
> T3), and/or Thyrolar (which is a synthetic T4:T3 combo)
>
> also, do you have any insight into what happened to the
> recent shortage (stoppage?) of Thyrolar, and if you do,
> would you kindly share it with us. thank you in advance

Thyrolar has always been spotty on availability. IMHO,
Thyrolar has too high of a T3 to T4 ratio. Most patients can
find it if they call around to various pharmacies.

The vast majority of hypothyroid patients do not require any
extra T3. A small (but vocal) number of patients have
improvement of symptoms if a small amount of T3 is added. I
find this much easier to adjust if I simply write for
Cytomel separately.

That way the T4, T3 and TSH levels can be adjusted and we
can have better consistency from month to month compared
to Armour.

If you are using Synthroid + Armour, you probably are seeing
less variability because a large fraction of your thyroid
replacement is relatively stable. The people taking Armour
(or Westhroid) as their only thyroid source will have more
difficulty. You can improve the long term stability of
dosing with Synthroid (or Levoxyl) + Cytomel combo.

Cheers, William C Biggs, MD
 
William C Biggs MD wrote:

> willbill wrote:

>> out of honest curiosity (and i'm NOT trying to start any
>> fights!), do you ever prescribe Armour to your own
>> patients? if not, why not?

> I used to, but not any more.

why am i not surprised by this?

also, thank you for responding. :)

too bad you didn't xpost to the thyroid n/g. :(

but i promise i won't do anything funky!

(like xposting it by myself)

i hope you like the word "funky" coz i do. :)

<i'd also like to say "JFC and LOL" but that's likely to set
some here (most?) against me. :( >

shades of a t2 dude (now deceased) who used to use
"minerals" in his handle. out of honest curiosity, did you
ever post to/with him on misc.health.diabetes?

>
> Armour is WAY too variable in potency from one batch to
> another.

maybe

but that's been at least as true for *ALL* of the synthetic
T4 meds in the fairly recent past, and afaik was *the* key
reason for the FDA's recent decision of forcing *ALL* of the
synthetic T4 producers to tighten up their act

my own hunch is that it's because of your own medical school
training and your own belief in the "goodness" of new meds

(anyhow what is it now, already 2 years ago now since the
FDA decreed "tighter compliance"? and afaik, the bloody
company that makes Synthroid (which is what i'm presently
using for synthetic T4), *STILL* hasn't met the new FDA
guidelines! but i could be wrong on this, given that i don't
do constant searches on this issue, whereas you're in the
biz and more likely to have a clue)

> It is a living nightmare to keep the levels steady with
> Armour. I can't imagine treating hundreds of patients with
> thyroid levels creeping all over the map.

OK. i won't take exception with that

but then again...

you're the one with the clinical experience on this issue,
and i've only been using an Armour/Synthroid combo for a
little over a year now

i started with only Armour (dessicated pig thyroid T4:T3
4:1) for 6 months

then to only Cytomel (pure T3) for 3 months

and now a combo of Armour/Synthroid for the last 15+ months.
this last month i got my 1st bottle of 175 mcg Synthroid and
am in the process of switching from 125 mcg Synthroid to the
175 mcg Synthroid size. (which is my "big" size, and which i
split 2 ways)

since i've still got a fair amount of 125 on hand, i set it
aside and am currently checking out the potency of the new
175's that i just got

with the 125's, i was taking .5 grain of Armour and a
nominal 88 mcg of Synthroid and getting decent symtoms (and
blood test results)

with the 175's and by going by "seat of the pants" symptoms
(primarilary that i've not got hyper symptoms), i'm already
up to a nominal 94 mcg of Synthroid (i go up by 3 mcg at a
time and hold it there for roughly 3 weeks, and yes i'm
holding my Armour at .5 grain/day)

>> after all, Armour is the cheapest source of T3

> Not after you include the costs of extra doctor visits and
> lab testing.

doc, you need to engage brain

if one starts with a combo of Armour and synthetic T4 (as i
did), then Armour is the cheapest way to get some T3 into
your routine

why can't you bloody docs understand that?

but yes, is that important?

my own answer is that i suspect it is

but i haven't a clue (other than my insulin experience), and
i'm too old to be willing to blow away 10 or more years with
poor health due to my being on only synthetic thyroid meds

i have, however, taken insulin for an exceptionally long
time with few or no "diabetic complications", and that
tells me that taking at least some dessicated pig thyroid
med (a.k.a. Armour Thyroid) is *very* likely to be a
significant plus

>> in the USA (vs. either Cytomel (which is pure synthetic
>> T3), and/or Thyrolar (which is a synthetic T4:T3 combo)
>>
>> also, do you have any insight into what happened to the
>> recent shortage (stoppage?) of Thyrolar, and if you do,
>> would you kindly share it with us. thank you in advance
>
>
> Thyrolar has always been spotty on availability. IMHO,
> Thyrolar has too high of a T3 to T4 ratio. Most patients
> can find it if they call around to various pharmacies.

thank you for this comment. :)

>
> The vast majority of hypothyroid patients do not require
> any extra T3.

i can believe that! :)

otoh, my experience with insulin convinces me to only
somewhat agreed

> A small (but vocal) number of patients have improvement of
> symptoms if a small amount of T3 is added. I find this
> much easier to adjust if I simply write for Cytomel
> separately.

OK and i can believe that. fwiw, i got my doc to start me on
only Armour (T4:T3 4:1) for the 1st 6 months, then switch to
only Cytomel (pure T3) for 3 months

my T4F and T3F number were clearly unbalanced at the end of
my use of only Armour, and we never bother to test at the
end of my use of only Cytomel (pure synthetic T3) coz it was
clearly not helping my worsening stiff joint problem(s)

>
> That way the T4, T3 and TSH levels can be adjusted and we
> can have better consistency from month to month compared
> to Armour.

again, you're the one with the significant clinical
experierce and not me

but given my insulin experience, i'm betting the other way.
i.e. that having *some* Armour throid in one's routine is
highly likely to be a significant plus

>
> If you are using Synthroid + Armour, you probably are
> seeing less variability because a large fraction of your
> thyroid replacement is relatively stable.

in another 2 or 3 weeks i'll return to using up the last of
my 125 mcg Synthroid size (split 2 ways)

i'm guessing that the new 175's are MUCH more potent than my
older 125's. :(

i have enough of the 125's left to make an accurate
assesment :)

bill t1 since '57

> The people taking Armour (or Westhroid) as their only
> thyroid source will have more difficulty. You can improve
> the long term stability of dosing with Synthroid (or
> Levoxyl) + Cytomel combo.
>
> Cheers, William C Biggs, MD
 
On Wed, 30 Jun 2004 14:08:12 -0500, willbill <[email protected]> wrote:

> William C Biggs MD wrote:
> > willbill wrote:
> >> after all, Armour is the cheapest source of T3
>
> > Not after you include the costs of extra doctor visits
> > and lab testing.
>
> doc, you need to engage brain
>
> if one starts with a combo of Armour and synthetic T4 (as
> i did), then Armour is the cheapest way to get some T3
> into your routine
>
> why can't you bloody docs understand that?

Color me confused by your reaction; I think the doc was
suggesting that the total cost of ownership (so to speak) is
more pricey for Armour, since in his experience there are
additional doctor visits and lab tests required because the
doses aren't stable, where more expensive meds that are more
stable are cheaper in the aggregate given the smaller number
of doctor visits and lab tests.
 
Hi Bill,

I appreciate your courtesy.

> shades of a t2 dude (now deceased) who used to use
> "minerals" in his handle. out of honest curiosity, did you
> ever post to/with him on misc.health.diabetes?

I remember "Speaker to Minerals" , but I can't recall if I
ever posted to him.

> (anyhow what is it now, already 2 years ago now since the
> FDA decreed "tighter compliance"? and afaik, the bloody
> company that makes Synthroid (which is what i'm presently
> using for synthetic T4), *STILL* hasn't met the new FDA
> guidelines! but i could be wrong on this, given that i
> don't do constant searches on this issue, whereas you're
> in the biz and more likely to have a clue)

Actually Synthoid did complete the NDA process last year.
There hasn't been any change in the formulation. All of this
was an exercise in paperwork for the drug companies, with an
exception for Levothroid. Levothroid quit production, then
the company that made Levothroid began relabeling a
different product under the old name Levothroid.

> >> after all, Armour is the cheapest source of T3
>
>
> > Not after you include the costs of extra doctor visits
> > and lab testing.
>
>
> doc, you need to engage brain
>
> if one starts with a combo of Armour and synthetic T4 (as
> i did), then Armour is the cheapest way to get some T3
> into your routine

Bill, I am including the "total cost of ownership" here.
This would include the costs associated with leaving work,
paying for a doctor visit, paying for additional lab
testing, etc to determine whether the change was
satisfactory.

Given the unpredictable results we see with Armour thyroid,
it requires more testing and thus more total cost. If we
decide to not bother testing, then it would be cheaper, but
risk subclinical hypo or hyperthyroidism.

Perhaps you are retired (so your time is worth zero?) , and
perhaps most of the additional lab and doctor costs are paid
by insurance. In that case the costs DID occur, but you have
shifted them to someone else.

>
> why can't you bloody docs understand that?
>
> but yes, is that important?

If we focus on your personal out of pocket costs, you may or
may not be correct. The total cost to SOMEBODY (you and/or
your insurance carrier) will be more.

Good luck on your thyroid dosing,

Best wishes,

William C Biggs, MD
 
willbill wrote:

<big snip>

> in another 2 or 3 weeks i'll return to using up the last
> of my 125 mcg Synthroid size (split 2 ways)
>
> i'm guessing that the new 175's are MUCH more

^^^^^^^^^^^^^^

> potent than my older 125's. :(

it pains me when i make a major posting error, but it's
hard not to not make occasional posting errors when
posting on n/g's

the above should read "MUCH *less*"

bill